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ABSTRACT
THE DISCOVERY AND STUDY OF FLUVIRUCIN B1 POLYKETIDE SYNTHASE
SEPTEMBER 2014
TSUNG-YI LIN, B.S., NATIONAL TAIWAN UNIVERSITY
M.S., ANATOMY AND CELL BIOLOGY, NATIONAL TAIWAN UNIVERSITY
Ph.D., CHEMISTRY, UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Nathan A. Schnarr
Rapidly decreasing numbers of viable therapeutic leads in the pharmaceutical pipeline
demand new, sustainable methods for improved drug discovery and development. Despite vast
improvements in de novo drug design and target recognition, Nature remains the richest source
of small molecule therapeutics. Among many natural products, polyketides are not only the most
promising ones for developing new antibiotic leads, but also exhibit unusually high therapeutic
value ranging from clinical use as anticancer, antiviral, and immunosuppressant drugs.
Modular polyketide synthases (PKSs) are dedicated nano-machinery that can be
manipulated to produce a structurally diverse library for drug discovery programs. The ability to
manipulate these natural systems to produce novel metabolites rests largely on increased
mechanistic understanding of how these molecules are generated and how these processes can
be manipulated. As impressive as their pharmaceutical properties are, the biosynthetic
engineering potential of these compounds continues to draw widespread attention from the
research community. Although some success has been realized in terms of polyketide structure
diversification, severe limitations in engineered product output continue to impede efforts
toward practical combinatorial biosynthesis. This thesis is focused on understanding and
exploiting a new biosynthetic enzyme assembly and overcoming the engineering hurdles for
making novel polyketide metabolites.
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Fluvirucin B1, produced by Actinomadura vulgaris, is a 14-membered macrolactam active
against a variety of infectious fungi as well as influenza A. Despite considerable interest from the
synthetic community, very little information is available regarding the biosynthetic origins of the
fluvirucins. Herein, we report the identification and initial characterization of the fluvirucin B1
polyketide synthase and related enzymes.
The cluster consists of five extender modules flanked by an N-terminal acyl carrier protein
and C-terminal thioesterases domain. All but one of the synthase modules contain the full
complement of tailoring domains (ketoreductase, dehydratase, and enoyl reductase) as
determined by sequence homology with known polyketide synthases. Active site analyses of
several key components of the cluster are performed to further verify that this gene cluster is
associated with production of fluvirucin B1. This work will both open doors toward a better
understanding of macrolactam formation and provide an avenue to genetics based diversification
of fluvirucin structure.
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CHAPTER 1.
INTRODUCTION OF POLYKETIDES, POLYKETIDE SYNTHASE
AND ENGINEERING OF POLYKETIDE SYNTHASE

1.1 Background
The steady rise of drug-resistant bacteria poses one of the most serious health risks in the
21st century. Deaths due to drug-resistant infections has raised the attention of most public
health programs in the world, not only since deaths could have impact on human societal
resources but also treating drug-resistant infections are far more costly for economic reasons.1
Rapidly decreasing numbers of viable antibiotic leads in the pharmaceutical pipeline demand new,
sustainable methods for improved drug discovery and development. Despite vast improvements
in de novo drug design and target recognition, Nature remains the richest source of smallmolecule therapeutics. Among many natural products, polyketides are among the most promising
for developing new antibiotic leads.

1.2 Polyketides
Polyketides are a broad class of structurally diverse and biologically interactive natural
products which are produced by bacteria, fungi, and plants. They exhibit a wide range of
pharmacologically properties including antibiotic (erythromycin and its derivatives), anticancer
(epothilone B), and immunosuppressant (rapamycin) among others (Figure 1).2
Since their discovery, polyketides have received enormous attention from the scientific
community. It is estimated that there are about 10,000 known natural polyketides, and 1% of
them are potent compounds, a significantly higher hit rate than is generally observed for other
natural product classes (<0.001%). Given that polyketide-derived pharmaceuticals comprise 20%

1

Figure 1. Representative polyketide structures. Rifamycin, Erythromycin, and
Tetracycline are antibiotics. Lovastatin is a HMG-CoA reductase inhibitor (cholesterol
lowering). Epothilone is an antitumor compound. Rapamycin is an immunosuppressant.

of the top-selling drugs in the world, it is very reasonable to develop viable therapeutic leads
based on these compounds. However, due to the structural complexity of polyketides, they are
generally difficult to be synthesized chemically and also troublesome to be produced naturally
since the producing organisms are often hard to culture. 3,4
Despite all the difficulties with making polyketides, an alternative methodology has been
proposed once after the natural machinery for making polyketides was discovered. Previous
research has shown that polyketides are biosynthesized by repeated condensations from simple
acyl-derived metabolites followed by varying degrees of reductive modification to render their
structural and pharmacological diversity. Therefore, understanding the mechanisms involved in
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polyketide biosynthesis can provide the necessary knowledge for manipulating these natural
enzyme systems to produce novel metabolites. The enzymes responsible for making polyketides
are known as polyketide synthases, and the mechanism of polyketide biosynthesis is very similar
to the biosynthesis of fatty acids.

1.3 Polyketide Synthases
Polyketides synthases (PKSs) can be categorized into three different types based on the
protein architecture and biosynthetic schemes. Type I PKSs, also called modular PKSs, are
composed of multiple catalytic domains that are covalently linked together and they are
organized as modules to produce macrolides with highly varied structures. Type II PKSs are
multienzyme complexes assembled by stand-alone monofunctional enzymes, which utilize the
same catalytic center iteratively to produce a polyketone chain which can be further processed
into highly aromatized or oxidized products. Type III PKSs, also known as chalcone synthase-like
PKSs, are homodimeric enzymes that can catalyze the condensation reaction iteratively to
produce small aromatic molecules without acyl-carrier domains. This dissertation is mainly
concerned with components from type I PKSs.
Modular PKSs, whose configurations are reminiscent of an industrial assembly line,
contain various modules which are composed of similar domains, and the precise composition
and arrangement determine the molecular make-up of the polyketide products. Each module
represents a workstation in the assembly line and each domain functions as a worker at that
workstation. Domains in a PKS module are responsible for catalyzing individual reactions that not
only dictate the chain length of the polyketide but also control the functional groups present on
the polyketide backbone. Hence, the linear setup of modular PKS systems provides the alternative
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approach, which is to manipulate the modular PKS systems to produce novel metabolites like
constructing an industrial assembly line for producing new product.
The ability to manipulate natural systems to produce novel metabolites rests largely on
increased mechanistic understanding of how these molecules are generated in the first place.
Over the past 20 years, a number of research groups have focused on genetic, biochemical, and
structural properties of PKSs. 5,6 It is well established that modular PKSs utilize simple extender
units derived from malonyl-coenzyme A to assemble
polyketides

in

a

linear

fashion.

Among

several

characterized PKSs, the biosynthesis of the polyketide core
of erythromycin A, 6-deoxyerythronolide B (6-dEB) (Error!
Reference source not found.), has provided the paradigm
for understanding the structure and function of the PKSs
that are responsible for assembling complex polyketides.7

Figure 2. Structure of 6-dEB.

1.3.1 DEBS for Elucidating the Mechanisms of Polyketide Synthase
The 6-deoxyerythronolide B synthase (DEBS), which catalyzes the formation of 6-dEB,
consists of three large subunits, DEBS1, DEBS2 and DEBS3, each containing two modules greater
than 300 kD in size. A module is defined as the collection of enzymes required for elongation and
processing of each intermediate structure. There are 2 domains in the N-terminal loading module,
responsible for priming the synthase with a propionate starter unit, and 26 domains in the six
extender modules. Each extender module contains at least three essential domains: a
ketosynthase (KS), an acyl transferase (AT), and an acyl carrier protein (ACP). The AT domain
selects the appropriate carbon extender unit and transfers the units from an acyl-CoA to the
phosphopantetheine (Ppant) arm of ACP. The KS domain accepts the polyketide chain from the

4

Figure 3. Schematic diagram of 6-deoxyerythronolide B synthase (DEBS). DEBS contains
three polypeptide units each consisting of two modules which add two carbons to the
polyketide backbone, as illustrated. A loading didomain (LDD) delivers the propionate
starter unit to module 1. The thioesterase (TE) domain is responsible for cyclization/release
of the final product. KS = ketosynthase, AT = acyl transferase, ACP = acyl carrier protein, KR
= ketoreductase, DH = dehydratase, ER = enoyl reductase.
previous module and catalyzes chain elongation reaction by adding an ACP-bound extender unit
through decarboxylative condensation (Figure 3).
After the extender unit is added, it can be further processed by optional tailoring domains,
including ketoreductases (KRs), dehydratases (DHs), and enoyl reductases (ERs), to yield a
hydroxyl, enoyl, or methylene group at the β-position. Finally, the thioesterase (TE) domain that
is located at the C-terminus of DEBS module 6 promotes the macrocyclization event which
releases the final product, 6-dEB. From this mechanistic insight, it is clear that the order of
catalytic domains in a PKS module determines the structure and processing of the extender unit,
while the number of PKS modules dictates the size of the polyketide chain. The mechanistic logic
behind polyketide biosynthesis bodes well for rational manipulation of product structure. As a
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result, several groups have shown that genetic engineering of polyketide biosynthetic pathways
provides an attractive means of producing new polyketides.

1.4 Heterologus Expression and Genetic Engineering of Polyketide Synthase Genes
As mentioned above, modular PKS systems like DEBS provide ways to modify any portion
of the polyketide through altering the corresponding domains or modules on the genetic level.
However, several aspects need to be taken into account to make new polyketides. Firstly, one
needs to demonstrate that the expression of large multi-domain proteins is not hindered by the
host cell machinery, and secondly, that the post-translational modification of ACP can be properly
loaded by the phosphopantetheinyl transferase in the host organism. Thirdly, some precursor
biosyntheses are not universally available (methyl- and ethyl- malonyl CoA) and they may hinder
the polyketide production. Lastly, one needs to consider the transportation of the precursor and
product recovery.
The DEBS genes, isolated from the bacterium Sacchapolyspora erythraea, were cloned
independently by two groups in the early 1990s, 8,9 and were the first set of polyketide genes
expressed in a heterologous host. The DEBS system was expressed in Streptomyces coelicolor
CH999, a strain containing a chromosomal deletion of the entire actinorhodin biosynthetic gene
cluster, and was used as the host strain to prove the idea of heterolougus production.10 Later, 6dEB was further produced in an engineered E. coli strain, BAP1, which was engineered from an E.
coli-strain BL21 to encode the sfp gene, a promiscuous phosphopantetheinyl transferase from B.
subtilis. The discovery of the sfp gene solves the problem of the posttranslational modification
required for the ACP domain.3 Since then BAP1 is the primary E. coli strain serving as the
heterologous host for expressing polyketide synthase genes.

6

Figure 4. Schematic diagram of genetic engineering strategy for producing novel
compounds from DEBS1 modules

To date, a number of PKSs have been cloned, analyzed, and engineered by recombinant
DNA technology to make novel “unnatural” products. In DEBS, inactivation of specific domains
has been accomplished through site-specific mutagenesis. Additionally, domain deletions,
additions, and swaps have been achieved via genetic engineering efforts (Figure 4).11 Because the
polyketides synthesized by these modular PKSs resemble each other, strategies have been
developed whereby modules of one PKS would recognize and process the structurally related
intermediates from other PKSs. To elaborate, they can be applied into:
1. Manipulation of polyketide chain length: For reducing chain length, it was reported
that unnatural triketide and hexaketide lactones could be biosynthesized by a
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deletion mutant comprising DEBS modules 1 and 2 + TE and modules 1 to 5 + TE
respectively, indicating that TE can act on a variety of chain lengths (C6–C15)12. For
extending chain length, four different novel octaketides were biosynthesized by
adding rapamycin module 2 or 5 between DEBS modules 1 and 2.13
2. Manipulation of building blocks: As preivously mentioned, incorporation of the
carbon extender unit is determined by the AT domain. As a result AT is the most
common domain engineered for domain replacement, in which the native AT domain
is replaced with another AT with different starter or extender unit specificity. For
example, nearly all six of the methylmalonyl-specific AT domains in DEBS have been
successfully replaced by malonyl-specific AT domains from the rapamycin PKS to
generate 6-dEB or erythromycin analogs lacking the corresponding methyl
branches.14-17
3. Manipulation of the β-carbon processing activities: In this category, all of the
strategies mentioned above have been applied in DEBS manipulations. More
specifically, inactivation of the ER domain in module 4 can generate the olefin at C-67 of the erythromycin derivative.18 Deletion of the KR domain in module 5 generates
a C-5 keto derivative of 6-dEB19 and the swap of the KR domains in modules 2, 5, and
6 with rapamycin DH+KR produces C-10-11, C-4-5, and C-2-3 olefin derivatives of 6dEB.20 Similarly, the replacement of KR domain in modules 2 with a DH+ER+KR unit
results in C-10 deoxy 6-dEB analogs.16
Furthermore, combining heterologous PKS domains into DEBS can create functional
hybrid PKSs and result in multiple modifications of 6-deoxyerythronolide B as well as generating
over 100 novel analogs.16, 21 The approaches further indicate that the modules of DEBS can be
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altered separately, expressed on different plasmids and combined together to produce unnatural
polyketide products.

1.5 Polyketide Synthase Engineering Hurdles
However, PKS engineering is not always successful. For example, the target compounds
of domain addition strategies have only about 3–5% production efficiency compared to the
normal polyketide products. In fact, the parent “unextended” polyketide is the major product
because the extension module is bypassed within the DEBS multienzyme system. In an attempt
to alter AT domains, McDaniel and coworkers failed to engineer a malonyl-AT domain in DEBS
module 4 by using several different domain junctions.22 In the multiple modification experiments,
the yields of the modified products dropped significantly when the number of combined
mutations increased and, discouragingly, only 5 of the 21 triple mutant combinations reached
detectable levels of polyketides, which may mean that multiple modifications on the polyketide
structure are generally disfavored with this system.
Previous efforts have pointed out that the substrate selectivity and protein-protein
interactions within a module or between modules play critical roles in polyketide biosynthesis.
Because the strategies described above often require making changes in module composition to
achieve the desired polyketide structure modifications, it is likely that the diminishing yields come,
at least in part, from the disruption of 3-dimensional protein architecture.

1.6 Hypothesis
Successful biosynthetic engineering efforts will undoubtedly require methods which do
not disrupt native protein architectures. The idea was bolstered by comparison of the inactivation
and deletion of the KR6 domain in DEBS. A point mutation at the catalytic serine residue gave only
the targeted analog, whereas the deletion of the whole domain affected the specificity of the
9

adjacent AT domain and led to unexpected products. 23 To achieve this, techniques must be
implemented where maximum product diversity can be achieved through manipulation of existing
enzyme activities without introducing heterologous components.

However, many fashionable

assemblies lack the elaborate modular compositions necessary to access the full range of
functionalities. For instance, DEBS module 4 is the only module in that system containing all three
tailoring domains (KR, DH, and ER) similar to mammalian fatty-acid synthase (FAS).24-28 All others
possess, at most, a single KR which limits the possible chemical outcomes to either the naturallyformed hydroxyl moiety, or a ketone functionality if the KR is inactivated. In contrast, module 4
is capable of producing methylene, olefin, hydroxyl, and ketone groups simply by mutating activesite residues while keeping the overall 3-dimensional structure intact (Figure 5). With this in mind,

Figure 5. Schematic diagram of a mutational inactivation strategy for production of novel
compounds from modules containing the full compliment of β-processing domains. Alterations
in chemical structure are designed at the genetic level
our strategy relies on discovery and characterization of PKS systems harboring KR, DH, and ER
domains in the majority, if not all, of the active modules to maximize product diversification. As
these synthases naturally produce less pharmaceutically-desired, hydrophobic molecules, they
have generally received little attention so the PKS modules with the full array of tailoring domains
(KR, DH, and ER) are relatively rare amongst PKSs studied to date. The content of this dissertation
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will establish these biosynthetic machines as a powerful means to generate increased product
diversity and, ultimately, improved small-molecule drugs.
Recognizing that the flow of intermediates along a given PKS requires, in large part,
effective communication between neighboring enzymes, many groups have focused on
determining the associated recognition motifs that govern these interactions.29-31 One of the
current research thrusts in the field involves redesigning individual modules by swapping primary
sequence information, including these recognition motifs, in an effort to improve enzyme kinetics.
Although successful implementations of this approach are beginning to emerge, we thought that
there must be a way of obtaining product diversity without having to reinvent what Nature has
already provided. To do so, a strategy where product diversification is solely the result of domain
inactivation must be implemented. By leaving all recognition interfaces in their natural forms, the
problem of producing and shuttling intermediates along the synthase is reduced to one of
substrate selectivity. In addition to delivering improved yields of engineered products, such a
system will, for the first time, provide a systematic means of assessing the relative contribution of
substrate selectivity to the flow of structures from one module to the next in a full-length PKS.
In summary, the detail of this dissertation provides two vital missing pieces to the
polyketide engineering puzzle: 1) A unique PKS where a wide variety of polyketide structures can
be generated without introducing heterologous domains or linkers and 2) a facile method for
examining ketosynthase substrate tolerance using simple, and readily obtainable, thioester
substrates. The former takes advantage of the fact that the FAS-like PKS modules produce β-keto,
β-hydroxyl, and β-olefin functionalities on the way to the final β-methylene product. Therefore,
to access these desired intermediate structures, one must simply “turn-off” the appropriate
tailoring domain within the module via site-directed mutagenesis. Most importantly, all proteinprotein interactions and native linkers remain intact, thus allowing for direct determination of the
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relative impact of chain transfer (in other words, KS substrate selectivity) on engineered
polyketide production.
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CHAPTER 2.
THE NEW TOOL FOR PKS ENGINEERING: FLUVIRUCIN B1 PKS
AND GENOMIC INFORMATION ANALYSIS

2.1 Introduction

Over the past several decades, researchers have devised numerous methods for
manipulating PKS processes in an effort to diversify product structure and, ultimately, biological
activity 1 - 5 . Although some success has been realized toward this end, decreased yields of
engineered products have limited the scope and efficacy of these methods. At this point it is clear
that the two primary factors leading to low yields are substrate selectivity of downstream
enzymes and disruption of protein-protein interactions when heterologous enzymes are
introduced.6-11 To circumvent the latter, strategies are needed where genetic alterations can be
introduced without disrupting the native three-dimensional PKS architecture.
For modular polyketide synthases this means unearthing assemblies which bear the full
complement of tailoring domains (KR, DH, and ER), similar to mammalian FAS, in most, if not all,
active modules. Carefully executed mutagenesis of key active site residues should result in all
possible β-functionalities while leaving the native protein-protein interactions intact (Figure 6).
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Figure 6. Schematic diagram of a mutational inactivation strategy for production of
novel compounds form fatty acid-like PKS modules. Alterations in chemical structure
are designed at the genetic level.

Therefore, PKSs that produce largely unfunctionalized polyketides (i.e. methylenes at most βpositions) may provide optimal engineering potential.

2.2 Fluvirucin B1 PKS

Fluvirucin B1 is 14-membered macrolactam produced by Actinomadura vulgaris with
moderate to good antifungal and antiviral
activities (Figure 7).12-14 Following assembly
of the core macrocycle, a single 3-amino3,6-dideoxy-L-talopyranose is appended to
the sole exocyclic hydroxyl group. The lack
of additional ring functionalities peaked our
Figure 7. Structure of fluvirucin B1 aglycone and
interest as we hypothesized that nearly all

fluvirucin B1
17

active modules should contain the FAS-like domain organization where KR, DH, and ER are all
present. If one were to consider PKS systems as evolutionarily connected to FAS, the fluvirucin
synthase may represent an early link between the two. As a result, we were motivated to explore
the biosynthetic origin of fluvirucin B1 with the ultimate goal of providing a platform for polyketide
engineering that circumvented the need for incorporation of heterologous domains to achieve
maximal product diversity.

2.3 Results and Discussions

2.3.1 Hypothesis

From the core structure of fluvirucin B1, we hypothesized that the producing PKS would
consist of five extender modules assuming that a β-alanine derivative is used as a starter unit in
the process. The sole hydroxyl group would therefore arise from a module harboring only a KR
domain while all other extender modules would contain the full compliment of KR, DH, and ER
domains (Figure 8). Based on the positions of macrolactam ring substituents, we expected that:
(1) the first and last modules contained ethylmalonyl-specific AT domains, (2) the second and
fourth modules incorporated malonyl groups, and (3) the third module utilized methylmalonate
(Figure 8). Finally, ring closure was most likely achieved via a C-terminal thioesterase (TE) domain
as is the case with similar macrocyclic polyketides.15-17 To test these hypotheses and determine
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Figure 8. Predicted tailoring domains and AT selectivities for each fluvirucin B1 synthase
module based on the fluvirucin B1 aglycone structure
the precise arrangement of enzymes within the assembly, we set out to identify and characterize
the fluvirucin B1 biosynthetic gene cluster.

2.3.2 Genomic Sequencing and Bioinformatic Analysis

To do so, the producing organism, Actinomadura vulgaris, was cultured following
published procedures.12-14 Genomic DNA was isolated and sequenced (Beckman Coulter
Genomics) affording 436,311 overlapping sequence fragments. These sequences were partially
assembled resulting in 444 consensus sequences ranging in size from 5000 to 170,000 base pairs.
We then utilized bioinformatic analyses to identify open reading frames that containing PKS
proteins or domains in silico translation. The relatively large size of PKS constructs allowed us to
quickly identify potential hits by searching each assembled sequence for open reading frames of
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at least 4000 base pairs. Our search identified several PKS gene clusters, one of which contained
the expected size and module composition of the proposed fluvirucin PKS.
For the proposed fluvirucin PKS, we initially found 5 contigs (33, 60, 1912, 3721, 3776)
partially covering the putative PKS gene cluster (Figure 9). As it shows in Figure 9, the putative

Figure 9. Putative gene cluster of fluvirucin PKS. FluA: module 1 and 2; FluB: module 3 and
4; FluC: module 5; D: Decarboxylase; G: Glycosyl tranferase; R: PKS regulator; P: proline
iminopeptidase
gene map, it consists of two uncertain areas to be further investigated. For the first gap between
the contig 3721 and 33, we performed a genomic PCR experiment to obtain the missing sequence.
Two primers were designed for this purpose: forward primer (ATCTCGACTGCTACGCATCC) is at
the putative DH domain sequence of module 3; reverse primer: (CCCGAAGTTGGATTTGACC) at the
putative KS domain in module 4. The PCR experiment was successful, and we isolated an amplicon
(4524 bp) and then further sequenced it to confirm that the missing gap was indeed flanking by
the contig 3721 and 33. For the second gap, we conducted a less stringent search within the
contigs we established, and we found that the contig 112 containing a putative crotonyl-coa
reductase and some similar sequence to module 2 within contig 3776. We then manually adjusted
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the sequence information based on the frequency and the degree of disagreement, and we
proposed the new putative gene culster of fluvirucin B1 PKS (Figure 10).

Figure 10. Gene organization for the fluvirucin B1 PKS cluster. The table summarizes the
gene cluster organization and gene products identified along with comparison to known
homologs.

2.3.3 Fluvirucin B1 PKS Genes

Three modular PKS genes, flu A-C, were found to contain an arrangement and
composition of domains consistent with the expected fluvirucin PKS assembly (Figure 10).
In addition, several PKS-associated genes were uncovered within the cluster including a
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pair of transciptional regulators (fluE, fluG), a glycosyl transferase (fluF), a decarboxylase
(fluI), and a drug transporter (fluD) (Figure 10). The fluJ sequence shows high similarity to
crotonyl-CoA reductases and likely plays a role in ethylmalonate generation as is required
for fluvirucin B1 biosynthesis.
FluA contains modules 1 and 2 of the fluvirucin B1 assembly. As expected, module
1 has the full compliment of tailoring domains (KR, DH, and ER) while module 2 possesses
only a KR domain putatively leading to the sole hydroxyl group on the macrolactam ring.
A single loading ACP is found at the N-terminus of FluA similar to the vicenistatin PKS
which utilizes an α-methyl-β-alanine starter unit.18
FluB contains modules 3 and 4 of the fluvirucin B1 PKS. Both modules contain KR,
DH, and ER domains as would be predicted from the fluvirucin core structure. Finally,
FluC consists of module 5 and a C-terminal TE domain. Module 5 again has all three
tailoring domains consistent with the lack of functionality at the corresponding
macrolactam ring position. As described in detail below, modules 1, 3, and 5 are
extremely similar to each other in terms of primary structure as are modules 2 and 4 but
similarities drop significantly when comparisons are made between these two groups
(Group1-module 1, 3, 5; Group2-module 2, 4). It is therefore tempting to speculate that
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the fluvirucin B1 synthase is composed of modules arising from two separate evolutionary
ancestors; one leading to modules 1, 3, and 5 and another leading to modules 2 and 4.

2.3.4 AT Selectivities

Extender unit selectivity for AT domains provides compelling evidence for any link
between a given PKS assembly and its associated polyketide product. Using, the SEARCHPKS
program developed by Mohanty and coworkers, probable coenzyme A substrates were
determined for each of the five putative fluvirucin B1 synthase AT domains.19 To our delight, all of
the predicted AT domain specificities were consistent with the fluvirucin B1 core structure (Table
1). Specifically, modules 2 and 4 showed high sequence similarity with malonyl-specific AT
domains while module module 3 was predicted to utilize methylmalonyl-CoA. Modules 1 and 5
returned a single hit for ethylmalonate specificity amidst several methylmalonyl-specific AT
domains. This is most likely due to the considerably lower abundance of ethylmalonyl-specific
ATs relative to methylmalonyl-specific ones rather than a true indication of relaxed specificity.
These results, together with the observed tailoring domain patterns, provided the necessary
evidence to link this polyketide synthase with the biosynthesis of fluvirucin B1.
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Table 1. Expected AT Specificities : Results from SEARCHPKS
Mod 1

Mod2

Mod3
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Mod4

Mod5

2.3.5 KR Domains

The Keatinge-Clay lab previously uncovered primary sequence patterns associated with
different types of ketoreductase domains commonly found in modular PKS systems.
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Examination of the fluvirucin KR sequences within this context revealed that all five align with the
B1-type KR sequence pattern (Figure 11). This KR family is generally observed when the KR works
in concert with other tailoring domains such as DH and ER, which is again consistent with the
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Figure 11. Protein homology analysis of Flu-KR Sequence. KR domain comparison
between Fluvirucin modules and other B1 type KR domains. The homology analyses are
done by Clustal Omega method of EMBL-EBI website, compared with the results in the
reference. (Note: DH, functional; dh, nonfunctional PKS abbreviations: Ave: Avermectin,
Tyl: Tylosin, Asc: Ascomycin, Rap: Rapamycin, Flu: Fluvirucin B1
expected enzyme composition for fluvirucin PKS modules 1, 3, 4, and 5. Interestingly, the module
2 KR domain also shows B1-type sequence character despite the absence of DH and ER domains
from that module. This observation may further highlight the fascinating evolution of the
fluvirucin synthase as discussed below. These results, together with the observed tailoring domain
patterns and AT selectivities, provided the necessary evidence to link this polyketide synthase
with the biosynthesis of fluvirucin B1.

2.4 Experimental detail

2.4.1 Bacterial strains, culture conditions and DNA purification.

Actinomadura vulgaris was purchased through American Type Culture Collection (ATCC)
by the accession number ATCC 53715 and used as the source of DNA for shot-gun sequencing
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service and the cloning of Fluvirucin B1 polyketide synthase. The strain was cultivated at ambient
temperature in the liquid medium of ATCC Medium 172 (N-Z Amine with Soluble Starch and
Glucose), which contains 1% glucose, 2% soluble starch, 0.5% yeast extract, 0.5% N-Z amine type
A (Sigma C0626), 0.1% CaCO3. The growth of A. vulgaris in ambient temperature can be observed
after 3 days of culture. For genomic DNA extraction purpose, A. vulgaris was cultured for 6 days,
and then genomic DNA was extracted by using the MasterPure gram-positive DNA purification kit
(Epicenter, Madison, WI)

2.4.2 Genomic sequencing and bioinformatic analysis

The genomic DNA of Actinomadura vulgaris was collected and sent to Beckman Coulter
Genomics for the genomic services as the requested concentration (20mg total). Later, the
436,311 sequence fragments of genomic DNA were sent back and subsequently imported into
Geneious software (http://www.geneious.com/download). We then did the assembling function
to harvest 444 contigs to be further analyzed. We chose 4000bp as a cut-off value for open reading
frames and did in silico translation for those to obtain putative protein products. The putative
proteins were then analysis by protien BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) for
screening domains related to PKS. We found several gene clusters resemble to PKS function but
only 5 contigs fit into what we hypothesized for fluvirucin B1 PKS.
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The protein sequences of AT domains were defined by BLAST, and subject to the analysis
tool of SEARCHPKS (http://www.nii.res.in/searchpks.html). And the KR sequence were also
defined

by

BLAST

and

the

homology

study

were

done

by

using

ClustalW2

(http://www.ebi.ac.uk/Tools/msa/clustalw2/), a general purpose multiple sequence alignment
program for DNA or proteins.

2.4.3 Genomic PCR Procedure

The PCR reaction for the gap between module 3 and module 4 was performed in a 50 ul
reaction mixture containing: 1X Phusion GC buffer, 0.2 mM dNTP, 0.3 mM MgCl2, 3%DMSO, 1 uM
of

each

primer

(forward

primer:

ATCTCGACTGCTACGCATCC;

reverse

primer:

CCCGAAGTTGGATTTGACC), 1U Phusion Hot Start II DNA polymerase (Thermo scientific, USA) and
approximately 450ng of genomic DNA was added as template.
The thermal cycler (Mastercycler ep gradient, Eppendorf) was programmed according to
the following “2-steps” amplification profile: 3 min denaturation at 98°C, then 10 initial cycles of
10 s denaturation at 98°C, 5 min annealing and elongation at 72°C, followed by 27 cycles of 10 sec
denaturation at 98°C, 5 min + (5 sec/cycle) elongation at 72°C, and a final extension step at 72°C
for 5 min. The amplified DNA fragments (4524bp) were then subjected to 0.8% agarose gel and
single bands were excised and purified using QIAquick Gel Extraction Kit (QIAGEN, Germany)
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according to the instructions from the manufacturer. The amplified DNA fragments were then
purified, and directly inserted into the plasmid vector PCR-Blunt II Topo (Zero blunt TOPO PCR
cloning kit, Invitrogen). Finally the resulting plasmid was sequenced under regular procedures to
obtain the genomic information.
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CHAPTER 3.
THE CLONING AND HETEROLOGOUS EXPRESSION OF FLUVIRUCIN B1 PKS

3.1 Introduction

For the past decade, the biosynthesis community has struggled to capture the true
engineering potential of polyketide synthases despite a vast array of tools for separating, fusing,
and rearranging the component enzymes. Of the many techniques employed in reengineering
PKSs, three stand out as the primary means of genetic alteration: (1) Domain Swapping, (2)
Domain Addition, and (3) Domain Deletion/Inactivation (Figure 12).
Domain Swapping: This technique involves physically replacing an individual PKS enzyme
with one from another synthase. Most commonly used for AT domains, the key to effective
domain swapping is a comprehensive knowledge of domain boundaries such that the surrounding
enzymes are unaffected. The primary downside to this procedure is that heterologous domains
often behave differently in their new environment. For instance, relaxed substrate selectivity has
been observed for swapped AT domains leading to diminished yields of the desired polyketide
products.1-2
Domain Addition: This technique is generally employed when an increase in enzyme
activity is desired. Many attempts have been made to incorporate KR, DH, and ER domains into
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Figure 12. Schematic diagram of polyketide engineering strategies. Left to right: Domain
deletion – KR knockout in DEBS module 2 results in a ketone functionality in place of the
native hydroxyl group. Domain swap – substitution of a malonyl-specific AT for the native
methylmalonyl-specific AT results in loss of a methyl group. Domain addition – replacement
of the native KR domain with a DH/ER/KR cassette results in loss of a hydroxyl group from the
final product. The latter two strategies require introduction of heterologous domains leading
to disruption of native protein-protein interactions. We seek a PKS where domain deletion
alone can provide maximal product diversity.
modules where they are absent, but the most effective strategy for domain addition involves
replacing the entire module with a heterologous one bearing the appropriate tailoring domains.
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In both cases, interaction issues between native and heterologous components often impede the
flow of intermediates within and between modules, resulting in significantly decreased product
yields.
Domain Deletion: As the simplest technique of the three, domain deletion/inactivation is
functionally the opposite of domain addition. The activity of any module containing at least one
tailoring domain (KR, DH, or ER) can be altered via mutation of active site residues or removal of
the entire enzyme.

It has been shown, however, that mutation (inactivation) provides

significantly higher product yields compared to removal (deletion), owing largely to the fact that
the former method maintains the native three-dimensional structure of the engineered module.3
This observation provided much of the initial motivation for this proposal and taking together
with the domain addition and swapping data, it is clear that disruption of PKS structure and
recognition motifs plays a significant role in diminished product yields.
To date, the most successful illustration of polyketide structure-diversification, executed
by McDaniel and coworkers, resulted in nearly 100 novel analogs of 6-deoxyerythronolide B.4,5 In
short, specific alterations to module components were genetically combined on unique plasmids
to produce unnatural polyketide products. They observed yields of mutant products ranging from
1-70% of the wild-type 6-deoxyerythronlide B. It should be noted that in all but 2 single mutants,
the relative yields were less than 50% and most of these fell into the realm of 20-30%. As a result,
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only about one-quarter of the triple mutant combinations afforded detectable levels of
polyketides. At this rate, access to the many thousands of conceivable engineered analogs is
beyond reach, thus underscoring the urgent need for strategies that address the primary
contributors to low product yields.
It is clear that decreased chemical output is a consequence of two primary barriers: (1)
substrate selectivity of downstream enzymes and (2) disruption of protein-protein interactions.
Engineering strategies that circumvent either or both of these issues will afford much needed
information regarding their relative contributions to low yields and ultimately lead to vastly
improved product diversity and output. However, tackling these engineering obstacles will first
require an in-depth understanding of their origins.
Therefore, we proposed a new strategy to overcome this hurdles, and we planned to
unearth a unique PKS system where a wide variety of polyketide structures can be generated
without introducing heterologous domains or linkers. The strategy takes advantage of the fact
that the FAS-like PKS modules produce β-keto, β-hydroxyl, and β-olefin functionalities on the way
to the final β-methylene product. Therefore, to access these desired intermediate structures, one
must simply “turn-off” the appropriate tailoring domain within the module via site-directed
mutagenesis. Most importantly, all protein-protein interactions and native linkers remain intact,
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thus allowing for direct determination of the relative impact of chain transfer (in other words, KS
substrate selectivity) on engineered polyketide production.
Upon our previous identification of the gene cluster for making fluvirucin B1, a fatty-acidsynthase-like PKS system, in Actinomadura vulgaris, it was soon appreciated as an interesting PKS
system with many unique biosynthesis attributes (Figure 13).6 It contains 5 modules of which 4
contain the full set of PKS tailoring domains. According to our hypothesis, it is an ideal system for

Figure 13. Schematic diagram for the putative fluvirucin B1 PKS. The assembly consists of
five extender modules flanked by an N-terminal loading ACP and C-terminal thioesterase
(TE) domain. FluA consists of the loading ACP, module 1 and module 2. FluB consists of
modules 3 and 4. FluC consists of module 5 and the TE domain.
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engineering strategy of single domain inactivation via site-directed mutagenesis. As a result, we
were motivated to explore the biosynthetic origin of fluvirucin B1 with the ultimate goal of
providing a platform for polyketide engineering that circumvented the need for incorporation of
heterologous domains to achieve maximal product diversity. Herein, we describe our effort to
unearth the assembly line of fluvirucin B1 PKS.

3.2 Result and Discussion

3.2.1 Cloning of Module 1 of Fluvirucin B1 PKS and PCR Optimization

To confirm the sequences obtained from partial assembly of the A. vulagaris genome and
with the ultimate goal of reconstituting the entire assembly in E. coli, we turned our attention to
cloning each module individually from genomic DNA. We firstly setup a genomic library (~800
colonies isolated) to screen for the genes that either contributed to or are associated with
fluvirucin B1 PKS. Unfortunately, all screening efforts came back with the indication that the
genomic library of A. vulagaris was contaminated by the genome of E. coli, and we suspect that it
was contaminated during the preparing processes of the genomic library.
After the failure of our genomic library, we began seeking alternative ways to clone the
gene of fluvirucin B1 PKS and one of which is genomic polymerase chain reaction (PCR). For
replicating the gene of interest from genomic DNA, it is not only hard to get single product but
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also difficult to amplify a long PCR product (>2kb) with high GC-content because GC-rich sequence
can easily to form secondary structure and render PCR useless. According to the genomic
sequencing information, the genome size of A. vulagaris is estimated about 12 million base pair
(bp), and it is relatively larger than the genome size of Streptomyces strain. For instance, the
complete genome of S. coelicolor strain A3(2) was decoded and published in 2002 7 , and the
genome was sequenced about 8 million bp with a GC-content of 72.1%. We expect the GC content
of A. vulagaris could be as high as S. coelicolor since they are close relatives under the order of
Actinomycetales, and indeed the sequence analysis showed FluA (11910bp) consists GC-content
of 71.3%, FluB (13128 bp) and FluC (7191bp) are 71.5% and 71.9% respectively. Considering all
these difficulties, we began our quest for cloning fluvirucin B1 PKS. Even though there is no
literature documented for long PCR protocol applied to GC-rich sequence, there are some aspects
of PCR can be optimized for our purpose. For instance, there are PCR methodologies for
temperature manipulations, different organic solvents as PCR additives, and primer-design
techniques, etc. We used all of PCR techniques mentioned above for cloning the assembly line of
fluvirucin B1 PKS.
Based on alignment with known PKS constructs and the in-silico analysis of restriction
enzyme sites, we were able to determine the effective sequence boundaries for each fluvirucin
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synthase module, and we began designing the PCR experiment and optimizing the PCR method
for each module.
For starter, we would like to describe our effort for cloning of module 1. We used the
sequence of module 1 as our amplification segment (6713bp, from the first ATG to the NotI site
as the boundary between module 2) and designed the PCR primers from the upstream and
downstream sequences within 1,000~1,500 bp to the boundaries of module 1. We then took the
arbitrarily defined sequence to Primer-BLAST on NCBI website to perform the computer-aided
primer-design in the default setting, and we obtained 20 sets of primers for cloning module 1.
Subsequently,

we

screened

all

the

primers

obtained

above

with

NetPrimer

(http://www.premierbiosoft.com/netprimer/) software, and selected the primers scored over 90
in NetPrimer. So, our first round primers are listed in Table 2:
As

soon

as

we

obtained

the
Table 2. The primer list for module 1

oligonucleotides in the list for cloning module
1, we performed several general PCR
reactions with Phusion Hot Start II DNA
polymerase. Initially, the primer sets of AvulMod1-F1&R1 and Avul-Mod1-F2&R2 did not
yield any meaningful products (Figure 14);

Avul-Mod1-F1: GGACATCGGCGGCGGCTTCG
Avul-Mod1-R1: GCGGGCGGCCAGGACCATCTT
Avul-Mod1-F2: CCGACTGCCTCCTGCGGGTG
Avul-Mod1-R2: GGACGTGGACGCGGCTCGGA
Avul-Mod1-F3: GCCACCACCAGCATCCGCAT
Avul-Mod1-R3: GTTCCGCCGATGAAGACGCC
Avul-Mod1-F4: GCCCTCCCAGTTCGGCTTCG
Avul-Mod1-R4: GGACTTCACGGTGCCCAGCC
Avul-Mod1-F5: ATCAACACGCTGGGCGGCAT
Avul-Mod1-R5: GGTTGGGGAGCACGGTCACG
Avul-Mod1-F6: TCCGTACCCGATCTCCGCCC
Avul-Mod1-R6: CCGCCCAGACATGACCGAACTG
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however, in the following PCR experiment with for the
permutation of primer matches (F3~F6 matched with
R3~R6), we observed that Avul-Mod1-F3, F5, F6 are
promising forward primers, R6 is a very promising reverse
primer, and R5 only effective when combined with F5
(Figure 15). Those positive results of our first attempt were
Figure 14. The PCR result for cloning subjected for the following cloning of TOPO-Blunt method
module 1-a. Lane 1-2: F1+R1, R2;

in order to identify the sequence of the PCR product, but

Lane 3-4: F2+ R1, R2. No promising
unfortunately the sequencing result did not suggest any
band observed above 6,000bp.
full-length sequence of module 1.

Figure 15. The PCR result for cloning module 1-b. Lane 1-4: F3+R3, R4, R5, R6; Lane 5-8: F4+
R3, R4, R5, R6; Lane 9-12: F5+R3, R4, R5, R6; Lane 13-16: F6+R3, R4, R5, R6. Lane 4, 12, 16
indicated R6 is a good reverse primer; Lane 9, 10, and 12 showed F5 is promising. The same
conclusion can be deduced on F3 and F6.
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With the data that some desired amplification of module 1 appeared in the DNA gel
analysis, we hypothesized that the low yield/non-full length amplification of the PCR experiment
could be caused by the GC-rich sequence within module 1. It has been suggested that DNA
amplification by PCR is frequently complicated with low yield and specificity by the GC content of
the target sequence, and the addition of some organic solvents like DMSO or betaine to PCR could
improve the amplification of DNA by reducing the secondary structures of GC-rich regions in the
DNA template or the primers.8 Therefore, we setup several PCR experiments with the primers
previously identified promising in amplifying the DNA of module 1, and we titrated the
concentration of DMSO from 0 % to 8 % in these experiment. To our delight, we got very promising

Figure 16. The PCR result for cloning module 1 with 5% DMSO. Lane 1: F1+R1; Lane 2: F1+ R6;
Lane 3: F3+R6; Lane 4: F4+R6; Lane 5: F5+R4; Lane 6: F5+R5; Lane 7: F5+R6; Lane 8: F6+R6.
The bands around 8,000bp indicated in Lane 3 to 8 are positive result, and the gel analysis
confirmed that DMSO indeed improves the amplification of DNA in our experiment.
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results in the PCR experiment with 5% DMSO (Figure 16). All PCR products with the predicted
length were excised, and then later confirmed the PCR results from Avul-Mod1-F3 + R6, F5 + R6
and F6 + R6 are true replications of module 1. Subsequently, we further improved our cloning
strategy not only by “touch-down” PCR methodology9 but also by designing a forward primer with
a NheI restriction enzyme site (a non-cutter for module 1), AMod1-NheI-F1 (see experiment
procedures), and we used in combination with Avul-Mod1-R6 in a similar setup of PCR to obtain
the pre-module 1 DNA fragment that can be purified, digested, and directly ligated into pET21b
without further steps of sub-cloning (Figure 17).

Figure 17. The plasmid map of Flu-module1 (pTL-A01)
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3.2.2 Cloning of Module 3 and 5 of Fluvirucin B1 PKS

With our successful experiments of replicating module 1 directly from genomic DNA, we
moved forward to a new and fast protocol to clone module 3 and 5: design proper primers with
restriction enzyme sites at the boundaries of each module. For cloning module 3, we designed the
primers in Table 3:
Table 3. The primer list for module 3
AMod3-EcoRI-F1: AAAAAAGAATTCGATGGCCACTGACGACAAGTTC
AMod3-R1: TTTTTTGACGTGGACGCGGCTCGGAC
AMod3-EcoRI-F2: AAAAAAGAATTCGATGGCCACTGACGACAAGTTCCGG
AMod3-R2: TTTTTTGTGGACGTGGACGCGGCTCGGAC
(Note: restriction enzyme sites were underlined and the additional “in-frame”
bases were emphasized in boldface.)
We did similar permutation of primer matches and the same titration of DMSO from 0%
to 8 % in the PCR for cloning module 3, and we successfully cloned out pre-module 3 DNA with
7% DMSO by the primer combination of AMod3-EcoRI-F2 and AMod3-R2. Later the PCR products
were digested and incorporated into pET-21b to obtain pTL-A03 (Figure 18). Next, we applied the
simple designing principle on primers for cloning module 5 (including the TE domain), we tested
all the primers listed in Table 4:
Table 4. The primer list for module 5
AMod5-NheI-F1: TTTTTTGCTAGCATGGCTGACGAA
AMod5-HindIII-R1: AAAAAAAAGCTTTCACGCGCCGTT
AMod5-NheI-F2: AAAAAAGCTAGCATGGCTGACGAAGAGAAG
AMod5-HindIII-R2: TTTTTTAAGCTTCGCGCCGTTCGA
AMod5-NheI-F3: AAAAAAGCTAGCATGGCTGACGAAGAGAAGCTCCTC
AMod5-HindIII-R3: TTTTTTAAGCTTCGCGCCGTTCGAACGCCC

44

Figure 18. The plasmid map of Flu-module3 (pTL-A03)
The permutation of primer matches were again deployed in order to find the best primer
set to clone the DNA of pre-module 5, and we observed the promising gel bands by the
combination of AMod5-NheI-F1 + R2, F2 + R3, F3 + R2, and F3 + R3 (data not shown). However,
the concentration of DMSO is slightly different than the previous titration for module 1 and 3,
because the PCR products of pre-module 5 were not amplified until the concentration of DMSO
was increased to 10%. This suggested that genomic PCR can be done in a relatively high
concentration of DMSO even if the high concentration DMSO can slightly inhibit the activity of
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DNA polymerase. In the end, pTL-A05 (Figure 19) was cloned out similarly as previously described
for module 1 and 3.

Figure 19. The plasmid map of Flu-module5 (pTL-A05)
As a summary for section 3.2.1 and 3.2.2, we were fortunately able to clone out Flumodule 1, 3, 5 directly with properly designed primers and various concentration of DMSO as
additives in a typical genomic PCR experiment. All three PCR products are amplified correctly and
verified by BLAST with the method provided in experimental procedures.
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3.2.3 Cloning of Module 2 of Fluvirucin B1 PKS and the Study of PCR Additives

Based on the strategy we developed, we applied to the same rules for designing primers
(Table 5) for module 2; however, we failed to obtain any substantial PCR products with every
possible match of forward and reverse primers and with different concentration of DMSO from
0% to 10%. We then hypothesized that the sequence within high GC content in module 2 (5160bp
with 70.6% of GC content) or the interactions between primers and DNA template may be the
cause for getting no/non-specific PCR products, and DMSO is not good enough to resolve the
problem. Therefore, we designed a series tests on PCR additives to overcome this problem. We
used the PCR condition for cloning module 1 with 8 different organic solvents as PCR additives in
the concentration range that previously suggested (Figure 20).10,11
Table 5. The primer list for module 2 (the first round)
Avul-Mod2-F1 CCACACCGGCAAGATCATCCTC
Avul-Mod2-F2 CCGGCAAGATCATCCTCACCATG
Avul-Mod2-F3 CCTCACCCCCGACAAGATCGA
Avul-Mod2-F4 TTCGTCCTCTACTCCTCCTCGG
Avul-Mod2-F5 CCTCACCACCACCGACATCAC
Avul-Mod2-F6 CGACATCACCCGCATCGAACA
Avul-Mod2-F7 ACCTCGCCACCGAACACCAGAC
Avul-Mod2-F8 CCTCCCGCCGAGGAGACCAAG
Avul-Mod2-F9 CGAGGAGACCAAGCCCCCGA
Avul-Mod2-F10 GCCATCCACCGCCACACCAC
Avul-Mod2-F11 ACCAACCCAGCGGCATGAGC
Avul-Mod2-F12 AAGCGGGACGCCCGTTCAAG
Avul-Mod2-F13 GCGACGCTGGTGTTCGACCA
Avul-Mod2-F14 AGGACAGGCTTCTGGACGGTT
Avul-Mod2-F15 GCCACCGAACACCAGACCCG
Avul-Mod2-F16 CCATCCACCGCCACACCACC
Avul-Mod2-F17 TCTGCTCGGGGTGGAGGACG
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Avul-Mod2-F18 GCCTCTCTGCTCGGGGTGGA
Avul-Mod2-F19 CGGGATGCGGTGCTGGTGTT
Avul-Mod2-F20 TCGCCATCCACCGCCACACCACC (same as F10 but longer)
-----------------------------------------------------------------------------------------------------Avul-Mod2-R1 GTACTGCTCGGACAGGAGGAC
Avul-Mod2-R2 GATCGGGAGGTTCCTGAGCTG
Avul-Mod2-R3 CGAACATGTCCACGTCGTCGT
Avul-Mod2-R4 GTAGTTGATGCTGCTCGCCAT
Avul-Mod2-R5 CGTGTGCATCGGCTCGAAGAT
Avul-Mod2-R6 GTAGTTGGTCTCGTACCCCCAGA
Avul-Mod2-R7 GCCATCCACAGGTAGCGGTTG
Avul-Mod2-R8 TAGACGGCGGACAGGGTGGG
Avul-Mod2-R9 GCCCCGAACCGCTTCCACTC
Avul-Mod2-R10 TCGGCCTTGTGGTCGCTGGAGA
Avul-Mod2-R11 ACCTTGTCACCGGCCTGCCA
Avul-Mod2-R12 GGGCCGGTCTTCAGCACGAC
Avul-Mod2-R13 TCGGCGTCGTACTGCTCGGA
Avul-Mod2-R14 GTCAGCCCGACCACACCGTG
Avul-Mod2-R15 TGTTGAACGCCCCGTCCAGC
Avul-Mod2-R16 CAGTACCCCGACCTTGCCGCT
Avul-Mod2-R17 CGGCGTCGTACTGCTCGGAC
Avul-Mod2-R18 GATCGGCGTTCTCCAGGGCG
Avul-Mod2-R19 CGGCGATCTCCTCGGGTTGC
Avul-Mod2-R20 GCCATCCACAGGTAGCGGTTGTCG (same as R7 but longer)
We observed that sulfolane offers more specific amplification whereas glycerol provides
with the best yield among all. After we found these phenomena/characteristics of organic
solvents in genomic PCR are superior to DMSO alone, we made a new PCR recipe consists of 15%
glycerol and 0.6M sulfolane as a new PCR additive mix for cloning module 2 with the primers
previously designed.
Followed by series of PCR experiments, nevertheless, we observed some improvements
in terms of specificity (data not shown), but we could not harvest enough DNA of pre-module 2
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Figure 20. The gel analysis of PCR additives examination based on module 1 PCR setup. All
panels contain 4 different concentrations and 1 lane of molecular marker
to be subjected into expression vector. Later, we designed the second round of primers for cloning
module 2 (Table 6), and we successfully cloned out the DNA of pre-module 2 with the primer
combination of Avul-Mod2-pF6+R7 and pF6+R17. The DNA of pre-module 2 was finally sub-cloned
into pET21b to construct the expression vector of Flu-module2, pTL-A02 (Figure 21).
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Table 6. The primer list for module 2 (the second round)
Avul-Mod2-pF1: CCATCAACACCCACACCCTCAG
Avul-Mod2-pR1: CCATCCACAGGTAGCGGTTGTC
Avul-Mod2-pF2: GCGTTCGTCCTCTACTCCTCCT (mis-primed at the end of mod4)
Avul-Mod2-pR2: AGGTAGCGGTTGTCGTACTGGTG (overlap with R7)
Avul-Mod2-pF3: TCATCCACATGTCCGTTATCGCAG
Avul-Mod2-pR3: ACCGTGTTGTAGTTGATGCTGCTC
Avul-Mod2-pF4: AACTGCTGGACCTGTTCGCCT
Avul-Mod2-pR4: CTCATCCTCCGCAAGCTAGTTGTC
Avul-Mod2-pF5: GGATGTGGTGCTCAACTCGCTG
Avul-Mod2-pR5: TGAGGCCGTAGAAGACGCTG
Avul-Mod2-pF6: CCCATCAACACCCACACCCT
Avul-Mod2-pR6: TCCGCAAGCTAGTTGTCCGA
Avul-Mod2-pF7: ATCACCCGCATCGAACAAGCC
Avul-Mod2-pR7: TTGAGGCCGTAGAAGACGCTG
Avul-Mod2-pF8: TGGATGTGGTGCTCAACTCGCT
Avul-Mod2-pR8: GTGTTGTAGTTGATGCTGCTCGCC
Avul-Mod2-pF9: AGATGCTCGCCGAACTGCTG
Avul-Mod2-pR9: TTGATCTGGTCGATGTGGCGG
Avul-Mod2-pF10: CACACCGGCAAGATCATCCTCAC
Avul-Mod2-pR10: ACGTCGCCGACCTTGATCTG
Avul-Mod2-pF11: AGGCAACCAACTCCTCGACACCGCCCT
Avul-Mod2-pR11: AACTCCGTGACCGCTGACCGCACCA
Avul-Mod2-pF12: ACGCCGGACACGACCGTATTGGGCAGA
Avul-Mod2-pR12: TCCCGTTCACGCCGCCGACGTTGTT
Avul-Mod2-pF13: TCCAAGCGGGACGCCCGTTCAAGGA
Avul-Mod2-pR13: TGGTCGATGTGGCGGGCACGGAACT
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Figure 21. The plasmid map of Flu-module2 (pTL-A02).

3.2.4 Cloning of Module 4 of Fluvirucin B1 PKS

As our effort for cloning module 1, 3, 5 and 2 being made, we simultaneously conducted
similar experiments for cloning module 4. We designed more than 70 primers (see 3.4
supplement section for the complete list) and tested in PCR experiments with DMSO or with
glycerol/sulfolane mix, but we could not flank any desired products after more than 2,000 PCR
run and ~200 gel analyses were casted. Then we reached to a conclusion that it may not be
realistic to directly clone module 4 as one piece in genomic PCR, we hypothesized that module 2
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and 4 may have the same evolution origin which makes them hard to be distinguished in the
amplification of genomic PCR. As a result, we began to seek an alternative way to grasp module 4
out of the sea of genomic DNA, so we adopt the concept of “divide and conquer” by replicating
module 4 DNA from two separate pieces, if not, as less pieces as possible, and merge each piece
as the original module 4 DNA by the molecular cloning techniques.
By performing in-silico analysis for the restriction enzyme site of module 4 DNA, we
quickly discovered a single cutter, MluI, located in the middle of the sequence, and we were
convinced that it can be served as a stitch point for ligation reaction. Therefore, we planned to
amplify two separate fragments of DNA, M4-1f and M4-2f, in genomic PCR and subsequently to
stitch them together. We then designed the proper primers for cloning each DNA fragment, and
we successfully replicated M1-4f with AMod4-HindIII-F1 + AMod4h-R6 and M4-2f with AMod4hF7 + AMod4-XhoI-R7 (primers).
After the DNA information of the two fragments were sequenced by primer walking,
however, we were surprised that M4-1f fragments are about 282bp shorter than we expected!
Later, we conducted a thoroughly sequence comparison between the short and the expected
sequence, and we found a repeated sequence, CCACCACCCA, located at the edge of the snipped
sequence. We later recognized that the region is occupied with high content of C or G, which could
contribute to secondary structure or G-quadruplex.12
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In order to solve the problem, we lowered the concentration of Mg+2 in PCR reaction and
extended the length of our primers, and we finally obtain the full length of M4-1f with AMod4HindIII-F8 + AMod4h-R10. Subsequently, M4-1f and M4-2f were ligated together to harvest
preM4 DNA, and the preM4 DNA was digested by NotI/XhoI and integrated with pET-21b to obtain
pTL-A04 (Figure 22).

Figure 22. The plasmid map of Flu-module4 (pTL-A04)
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3.2.5 Protein Expression

In conclusion, all five modules were cloned separately in pET vectors for expression in E.
coli. Overexpression of each module was observed in BL21(DE3) cells, and gel migration patterns
were consistent with calculated protein masses (Figure 23). The fact that E. coli seems to respond
well to these foreign genes bodes well for our future efforts aimed at generating fluvirucinderived structures in this heterologous host. In the near term, the ability to reliably produce
usable quantities of each module will greatly facilitate studies concerning the substrate
specificities and enzyme kinetics that govern fluvirucin B1 biosynthesis.

Figure 23. PAGE analysis of fluvirucin modules overexpressed in E. coli following Ni-NTA affinity
purification. Lanes are marked with the corresponding protein or blank pET21 vector. Mod =
Module. Approximate protein molecular weights: module 1 = 230 kDa, module 2 = 185 kDa,
module 3 = 220 kDa, module 4 = 240 kDa, module 5 = 254 kDa. % acrylamide = 7.0.
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3.3 Experimental Procedures

3.3.1 Bacterial Strains, Culture Conditions and DNA Purification.

Actinomadura vulgaris was purchased through American Type Culture Collection (ATCC)
by the accession number ATCC 53715 and used as the source of DNA for shot-gun sequencing
service and the cloning of Fluvirucin B1 polyketide synthase. The strain was cultivated at ambient
temperature in the liquid medium of ATCC Medium 172 (N-Z Amine with Soluble Starch and
Glucose), which contains 1% glucose, 2% soluble starch, 0.5% yeast extract, 0.5% N-Z amine type
A (Sigma C0626), 0.1% CaCO3. The growth of A. vulgaris at ambient temperature can be observed
after 3 days of culture. For genomic DNA extraction purposes, A. vulgaris was cultured for 6 days
and then genomic DNA was extracted by using the MasterPure gram-positive DNA purification kit
(Epicenter, Madison, WI)

3.3.2 General Procedure for PCR Experiment

PCR reactions were performed in a 50µl reaction mixture containing: 1X Phusion GC
buffer, 0.2mM dNTP, 0.3mM MgCl2, 0~3%DMSO, 1M of each primer, 1U Phusion Hot Start II DNA
polymerase (Thermo scientific, USA) and approximately 300~450ng of genomic DNA was added
as template.
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The thermal cycler (Mastercycler ep gradient, Eppendorf) was programmed according to
the following “3-step” amplification profile: 3min denaturation at 98°C, then 35~40 cycles of
10sec denaturation at 98°C, 30sec at annealing temp (depending by the primer set), Xmin (X=the
length of amplfication/1000) elongation at 72°C and a final extension step at 72°C for 3~5min. The
amplified DNA fragments were then subjected to 0.8%~1.1% agarose gel to verify the products. If
a single band of desired length were revealed, it would be excised and purified using a QIAquick
Gel Extraction Kit (QIAGEN, Germany) for any following analysis or cloning procedure.

3.3.3 Cloning of Module 1 of Fluvirucin B1 Polyketide Synthase

The PCR reaction for module 1 was performed in a 50µl reaction mixture containing: 1X
Phusion GC buffer, 0.2mM dNTP, 0.3mM MgCl2, 5%DMSO, 1µM of each primer (AMod1-NheI-F1:
AAAAAAGCTAGCATGAGCCAGTCCGGAAACAGCGAA;

Avul-Mod1-R6:

CCGCCCAGACATGACCG-

AACTG), 1U Phusion Hot Start II DNA polymerase (Thermo scientific, USA) and approximately
450ng of genomic DNA was added as template.
The thermal cycler (Mastercycler ep gradient, Eppendorf) was programmed according to
the following “2-step” amplification profile: 3min denaturation at 98°C, then 10 initial cycles of
10sec denaturation at 98°C, 5min annealing and elongation at 72°C, followed by 27 cycles of 10sec
denaturation at 98°C, 5min + (5sec/cycle) elongation at 72°C, and a final extension step at 72°C
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for 5min. The amplified DNA fragments (7221bp) were then subjected to 0.8% agarose gel and
single bands were excised and purified using a QIAquick Gel Extraction Kit (QIAGEN, Germany)
according to the instructions from the manufacturer. Subsequently, it was subjected to restriction
enzyme digestion of NheI and NotI and the digested products were ligated to pre-digested pET21b to obtain pTL-A01.

3.3.4 Cloning of Module 3 of Fluvirucin B1 Polyketide Synthase

The PCR reaction for module 3 was performed in a 50µl reaction mixture containing: 1X
Phusion GC buffer, 0.2mM dNTP, 0.3mM MgCl2, 7%DMSO, 1µM of each primer (AMod3-EcoRIF2:

AAAAAAGAATTCGATGGCCACTGACGACAAGTTCCGG;

AMod3-R2:

TTTTTTGTGGACGT-

GGACGCGGCTCGGAC), 1U Phusion Hot Start II DNA polymerase (Thermo scientific, USA) and
approximately 450ng of genomic DNA was added as template.
The thermal cycler was programmed as for module 1, and the amplified DNA fragments
(6338bp) were purified, and directly digested by EcoRI and NotI. The digested products were
ligated to pre-digested pET-21b to obtain pTL-A03.

3.3.5 Cloning of Module 5 + TE of Fluvirucin B1 Polyketide Synthase

The PCR reaction for module 5 was performed in a 50µl reaction mixture containing: 1X
Phusion GC buffer, 0.2mM dNTP, 0.3mM MgCl2, 10%DMSO, 1µM of each primer (AMod5-NheI-
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F3: AAAAAAGCTAGCATGGCTGACGAAGAGAAGCTCCTC; AMod5-HindIII-R2: TTTTTTAAGCTTCGCGCCGTTCGA), 1U Phusion Hot Start II DNA polymerase (Thermo scientific, USA) and
approximately 450ng of genomic DNA was added as template.
The thermal cycler was programmed as for module 1, and the amplified DNA fragments
(7196bp) were then extracted and subjected to NheI and HindIII double digestion. Finally, the
digested products were ligated to pre-digested pET-21b to obtain pTL-A05.

3.3.6 PCR Organic Solvent Study

The PCR condition and the operation of thermocycler are the same with the method for
cloning of module 1, except for the PCR additive was swap with the following organic solvent: 3%
, 6%, 10%, 15% (v/v) of DMSO; 0.15M, 0.3M, 0.6M, 1M of sulfolane; 5% 10% 15% 20% of glycerol;
0.5M, 1M, 2M 3M of betaine; 0.25M, 0.5M, 1M, 2M Of 1, 3-butanediol; 0.1M, 0.25M, 0.5M, 1M
of 1,5-pentanediol; 0.25M, 0.5M, 1M, 2M of xylitol; 0.25M, 0.5M, 1M, 2M of d-sorbitol, are used
in the PCR reaction.

3.3.7 Cloning of Module 2 of Fluvirucin B1 Polyketide Synthase

The PCR reaction for pre-module 2 was performed in a 50 µl reaction mixture containing:
1X Phusion GC buffer, 0.2mM dNTP, 0.3mM MgCl2, 15% glyerol, 0.5M sulfolane, 1µM of each
primer (Avul-Mod2-pF6: CCCATCAACACCCACACCCT; Avul-Mod2-R7: GCCATCCACAGGTAGCGG-
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TTG), 1U Phusion Hot Start II DNA polymerase (Thermo scientific, USA) and approximately 450ng
of genomic DNA was added as template.
The thermal cycler was programmed according to the following “stepdown” amplification
profile: 3min denaturation at 98°C, then 10 initial cycles of 10sec denaturation at 98°C, 30sec
annealing at 72-68°C, 6min elongation at 72°C where the annealing temperature was decreased
by 0.4°C per cycle, followed by 27 cycles of 10sec denaturation at 98°C, 30sec annealing at 68°C,
6min + (5sec/cycle) elongation at 72°C, and a final extension step at 72°C for 5min.
The amplified DNA fragments (6760bp) were then purified, and directly inserted into the
plasmid vector PCR-Blunt II Topo (Zero blunt TOPO PCR cloning kit, Invitrogen) to obtain pM2-444-3 (pTL-preM2). After obtaining pTL-preM2, the same PCR protocol was performed as stated
above, except for using the following primers: AMod2-NdeI-F8: AAAAAACATATGACGCTGGTGTTCGACCAC; AMod2-HindIII-R1: TTTTTTAAGCTTGGACGCGCCGAGCTGGTC. The DNA
amplicons (5265bp) were digested by NdeI and HindIII, and then were ligated to pre-digested pET21b to obtain pTL-A02.

3.3.8 Cloning of Module 4 of Fluvirucin B1 Polyketide Synthase

The PCR protocol for pre-module4 is the same as for pre-module2, except for using the
following primers: AMod4-HindIII-F8: AAAAAAAAGCTTCGGCAAGATCATCCTGACCATGC and
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AMod4h-R10: CGGGTACATGCCCAAGGAGTTGA are for M4-1f fragments (5863bp); AMod4h-F7:
CAACGCACAAGACATCCAACA

and

AMod4-XhoI-R7:

TTTTTTCTCGAGCAGGCCCTGGTCGATC-

AGCGAGAAGAGC are for M4-2f fragments (4339bp). M4-1f fragments and M4-2f fragments are
separately inserted into the plasmid vector PCR-Blunt II Topo to obtain pTL-M4-1f and pTL-M4-2f.
Later, the pTL-M4-1f plasmids were digested by HindIII and MluI to obtain M4-1f fragments again
to clone into pTL-M4-2f to harvest pTL-preM4.
Finally, the pTL-preM4 was digested by NotI and XhoI and ligated to pre-digested pET-21b
to obtain pTL-A04.

3.3.9 General Procedure for Protein Expression and Isolation

E. coli (BL-21) bearing the appropriate plasmid was grown in 1 L shake cultures of LBampicillin media at 37 °C until the OD600 was between 0.6 and 0.8. Overexpression was induced
by adding 200 μL of 1 M IPTG at appropriate induction temperature (see below) for 16 h. After
this point, all work was carried out at 4 °C. Cells were pelleted by spinning at 6000 rpm for 10 min
and resuspended in 10 mL of lysis buffer (20 mM TrisHCl, 150 mM NaCl, 1 mM Na2EDTA, 1 mM
EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1
μg/mL leupeptin, pH 8). Cells were lysed for five 30 sec intervals with a 60 sec cool down period
between each. Lysed cells were spun at 14,000 rpm for 60 min. The lysate supernatant was
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equilibrated with 3 mL of Ni-NTA bead slurry for 60 min. The mixture was then poured into a 15
mL column, and the supernatant was eluted. The column was then washed with two 15 mL
portions of wash buffer (50 mM phosphate, 300 mM NaCl, 50 mM imidazole, pH 8.0) and eluted
with 3 mL of elution buffer (50 mM phosphate, 300 mM NaCl, 250 mM imidazole, pH 8.0). The
purified protein was loaded onto a 100 kDa cutoff centrifugal concentrator, diluted to 15 mL with
storage buffer (100 mM Tris, 1 mM EDTA, 1 mM dithioerythritol, 10% glycerol, pH 8), and spun at
3000 rpm. Dilution and filtration was repeated a total of three times. Protein concentrations were
determined by Bradford assay with an average concentration of approximately 500 μM. Proteins
were ﬂash frozen and stored at −80 °C unl use.

3.3.10 Materials

All biochemicals, chemicals, and media were obtained from Fisher Scientific, all restriction
enzymes were obtained from New England Biolabs, and other molecular biological reagents were
obtained from Fisher Scientific, New England Biolabs, or Invitrogen. All PCR primers were
synthesized by Eurofins MWG Operon.
All DNA sequences were deposited in the GenBank database under the following
accession numbers: JX308234 (FluA), JX915256 (FluB), and JX448408 (FluC)
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3.4 Supplement Information for Cloning of Module 4

The Complete List of the Primers for Module 4
Part1: the following primers were designed for PCR when DMSO is applied.
Avul-Mod4-F1: CCGCACCCTCAGCAACCGCC
Avul-Mod4-R1: CAGCCATGCCGTCCCGCCTTC
Avul-Mod4-F2: CCCGCACCCTCAGCAACCGC
Avul-Mod4-R2: AGCCATGCCGTCCCGCCTTC
Avul-Mod4-F3: CGATTCTGCGTGGGCTGGCT
Avul-Mod4-R3: TGGATGGCGACGAGCGAGGA
Avul-Mod4-F4: CCCTCAGCAACCGCCACGAC
Avul-Mod4-R4: CCTCGGGCAGGGGTCCTCGG
Avul-Mod4-F5: CCGCTCAATCCCTCGCCTGG
Avul-Mod4-R5: TCTCCTCGACCTCGCGCAAACGT
Avul-Mod4-F6: CGCTGGAACGCCGTCTGACC
Avul-Mod4-R6: CGCTCCTTCTCCTCGACCTCG
Avul-Mod4-F7: TAAAGCGCCTGGTGTTGGCCTC
Avul-Mod4-R7: ATCTTGATCACACCGGCCACG
Avul-Mod4-F8: GTTCACCGCCATGGGTGCCA
Avul-Mod4-R8: CGTTCGGAGCCGTCAACCCAT
Avul-Mod4-F9: AGGAGACCAAGCCCCCGAC
Avul-Mod4-R9: GACTGGCAGGCCATGTGGATG
Avul-Mod4-F10: CGATCCACCGCCACACCAC
Avul-Mod4-R10: CAACGACTACGAGGTGGGCCGA
Avul-Mod4-F11: GCCTGCCCGCTCAATCCCTC
Avul-Mod4-R11: GAAGAACGCGGGGTCGAACTC
Avul-Mod4-F12: TCTGCTCGGGGTGGAGGACG
Avul-Mod4-F13: GCCTCTCTGCTCGGGGTGGA
Avul-Mod4-R12: CTCTTCGTCAGCCATGCCGTC
Avul-Mod4-R13: AAGGACCGTTCGGAGCCGTCAAC
Avul-Mod4-F14: ACGGGTGGCACAGGTGGTCT
Avul-Mod4-R14: ATCACCCGCTCCTGCGAAGGAC
Avul-Mod4-F15: CGATGGTGAGTTGGCGGCGT
Avul-Mod4-R15: GTGGATGGCGACGAGCGAGG
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Avul-Mod4-F16: GGTGTTCGCCGAGGTGGAGC
Avul-Mod4-R16: ACGCCGAACGACGACACACC
Avul-Mod4-F17: GTTCGCCTGGAACGGGGTGG
Avul-Mod4-R17: CCGACCGACTCCCACAACGC
Avul-Mod4-F18: GATCCACCGCCACACCACCG
Avul-Mod4-R18 GACCCCGACCGACTCCCACA
Avul-Mod4-F19: GATGGTGAGTTGGCGGCGTTGC
Avul-Mod4-R19: TGCCGTCCCGCCTTCCCTAA
Avul-Mod4-R20: CCGTTCCCAGTCCACCCCCA
Avul-Mod4-R21: CCGTTCGGAGCCGTCAACCC
Avul-Mod4-R22: AGTCCCGATCCCGCCCGTAC
-----------------------------------------------------------------Part2: the following primers were primarily designed for simple cloning as a full module.
AMod4-F1: AAAAA AGCGTGTCACCGGCAGCGGC
AMod4-XhoI-R1: TTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGA
AMod4-F2: AAAAAA TCCAGCGTGTCACCGGCAGCGGC
AMod4-XhoI-R2: TTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGAGAA
AMod4-F3: ACCTGCTCCAGCGTGTCACCG
AMod4-XhoI-R3: TTTTTTCTCGAGCAGGCCCTGGTCGAT (shorter and use HPSF purification when
synthesized)
AMod4-F4: CAAGCGGGACGCCCGTTCAAG
AMod4-XhoI-R4: TTTTTTCTCGAGCAGGCCCTGGTCGATCAG
AMod4-F5: ATGCCGGAGCCGTTCCTCGTA
AMod4-XhoI-R5: AAAAAACTCGAGCAGGCCCTGGTCGATCAG
AMod4-F6: AGGCCACTCGCCACCTCGAT
AMod4-XhoI-R6: TTATTACTCGAGCAGGCCCTGGTCGATCAG
AMod4-F7: CCGCCCTCCTTGACCGGGTA
AMod4-XhoI-R7: TTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGAGAAGAGC
AMod4-F8: CCTCCCGCCGAGGAGACCAA
AMod4-XhoI-R8: TTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGAG
AMod4-XhoI-R8-1: TTTTTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGAG
AMod4-XhoI-R8-2: TTTTTTTTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGAG
AMod4-XhoI-R8-3: TTTTTTTTTTTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGAG
-----------------------------------------------------------AMod4-F9: GATTCTGCGTGGGCTGGCTCG
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AMod4-F10: ATTCTGCGTGGGCTGGCT (like Avul-mod4-F3 but shorter and has lower GC% and use
HPSF purification)
AMod4-F11: TTCGGGGTTCACCGCCAT (last 8bp have resemble site within the target sequence)
AMod4-F12: TCACGGCGGTCTTCCACA (last 8bp only present once in the margin of target
sequence)
AMod4-F13: AAAAAACGCTCACGGCGGTCTTCCACA
AMod4-F14: AAAAAAGATTCTGCGTGGGCTGGCTCG
AMod4-F15: AAAAAACCTGCTCCAGCGTGTCACCG
AMod4-F16: TGATCACGGGTGGCACAGGT
AMod4-F17: GCATCTGCACCAGGCCACTC
AMod4-F18: CGGGTGGCATGACGAACCAG
AMod4-F19: CGGAGCCGTTCCTCGTACCT
AMod4-F20: CTCTGCCCATCAACACCCGCA
AMod4-F21: CGACGCTGGTGTTCGACCATC
AMod4-F22: GTGTTCGACCATCCCACGCC
-----------------------------------------------------------------Avul-Mod4-aF1: TCAAGCGTGCTACCGCCGACCT
Avul-Mod4-aF2: GGGACTACCTCAAGCGTGCTAC
Avul-Mod4-aF3: CGTGCTACCGCCGACCTTCAG
Avul-Mod4-aF4: GCGAGGTCGAGGCGAAGGATC
-------------------------------------------------------------------Avul-Mod4-bF1: TGCGTGGCGACGAGGTGTTC
Avul-Mod4-bF2: AGGGTGTCGGGTTGTCGCTGGT
Avul-Mod4-bF3: GGGAGGCGGTGCTGGTGTTC
Avul-Mod4-bF4: ATCACGGGGTGGGGGAGACG
Avul-Mod4-bF5: AGGTGTTCGCCGAGGTGGAGCT
Avul-Mod4-bF6: TGTCGTCGTTCGGCGTCAGC
Avul-Mod4-bF7: GACTACGCCTCGCACTCCGC
Avul-Mod4-bR1: ATGCCGTCCCGCCTTCCCTAAG
Avul-Mod4-bR2: GCAAACGTCGGTTGGCCTGCTG
Avul-Mod4-bR3: ACCTCGTAGTCGTTGGCGAAGGC
Avul-Mod4-bR4: TCGGCCCACCTCGTAGTCGTTG
Avul-Mod4-pF1: CTCGTACCTCTGCCCATCAACAC
Avul-Mod4-pR1: TTCTCTTCGTCAGCCATGCCGT
Avul-Mod4-pF2: ATCAACACCCGCACCCTCAG
Avul-Mod4-pR2: TAAGTCGTCCCGCTGCTGTC
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Avul-Mod4-pF3: CACACCGGCAAGATCATCCTGAC
Avul-Mod4-pR3: GGTTTCGAGTTGCTGTGGGAC
Avul-Mod4-pF4: ATGACGAACCAGTTGTCGGAAC
Avul-Mod4-pR4: TAAGGGGTTTCGAGTTGCTGTG
Avul-Mod4-pF5: GACGAACCAGTTGTCGGAACTC
Avul-Mod4-pR5: TTCCCTAAGGGGTTTCGAGTTG
Avul-Mod4-pF6: TCCTTGACCTCTGTCGAGTTGC
Avul-Mod4-pR6: GGATCTCGGTGAAACATTCCTC
Avul-Mod4-pF7: CCGTTCAAGGATCTCGGTTTC
Avul-Mod4-pR7: CCTTCCCTAAGGGGTTTCGAGT
Avul-Mod4-pF8: CAGTTGTCGGAACTCGACCTG
Avul-Mod4-pR8: CTCTCGATGGACTCCAGAGCA
Avul-Mod4-pF9: ACCAGTTGTCGGAACTCGACCT
Avul-Mod4-pR9: GCTGGAGATCCTCGGTCACTC
Avul-Mod4-pF10: CTCGCCTGGTAAGCAGCATC
Avul-Mod4-pR10: CGTGGTCACGTACAGGGTCTG
Avul-Mod4-pF11: CAACTCCTGGACGTCGCTCT
Avul-Mod4-pR11: AACCTGACCCTGCTCCCAAT
Avul-Mod4-sF1: ACTGACCTGGAGACGGCTGGTG
Avul-Mod4-sF2: GACGCCCGTTCAAGGATCTCG
Avul-Mod4-sF3: CCTGGACGTCGCTCTGACAATGC
Avul-Mod4-sF4: GGACGCCCGTTCAAGGATCTC
Avul-Mod4-sR1: GCGAGGAGCTTCTCTTCGTCAGC
Avul-Mod4-sR2: GTCCTCGGCCCACCTCGTAGTC
Avul-Mod4-sR3: GCTGGAGATCCTCGGTCACTCG
Avul-Mod4-sR4: GTAAGTCGTCCCGCTGCTGTCC
Avul-Mod4-cF1: GTGCTGGTGTCCCTGGTCTGC
Avul-Mod4-cF2: CATCAACACCCGCACCCTCAG
Avul-Mod4-cF3: CGTTCCTCGTACCTCTGCCCATC
Avul-Mod4-cF4: GGAGCCGTTCCTCGTACCTCTGC
Avul-Mod4-cF5: GAGCTGTTCGCCGATGGTGAG
Avul-Mod4-cR1: CTCCACGAACTCCTCCAGCACCT
Avul-Mod4-cR2: CCACGAACTCCTCCAGCACCTG
Avul-Mod4-cR3: GTTGTCCGCACTCACCTCCAACC
Avul-Mod4-cR4: CCACCTCGTAGTCGTTGGCGAAG
Avul-Mod4-cR5: CCTGCTGGAGATCCTCGGTCACT
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Part3. the following primers were designed for cloning module 4 into two separated half-parts
DNA, when a MluI site at 3343/3347 [GCGGCCGTGG A CGCG T CATGCCGCCG] of module 4 was
identified.
3a. For M4-1f fragments:
AMod4-HindIII-F1: AAAAAA AAGCTT GGCAAGATCATCCTGACCA
AMod4-HindIII-F2: AAAAAA AAGCTT CGTTCAAGGATCTCGGTTTC
AMod4-HindIII-F3: AAAAAA AAGCTT GCGTTCGTGCTCTACTCCTC
AMod4-HindIII-F4: AAAAAA AAGCTT CAAGATCATCCTGACCATGC
AMod4-HindIII-F5: AAAAAA AAGCTT TATCGCAGCTTCGACCTGAT
AMod4-HindIII-F6: AAAAAA AAGCTT CAGCTTCGACCTGATGGATG
AMod4-HindIII-F7: AAAAAA AAGCTT CGCAGCTTCGACCTGATGGATG
AMod4-HindIII-F8: AAAAAA AAGCTT CGGCAAGATCATCCTGACCATGC
(The following were used with HindIII-forward)
AMod4h-R1: AGAGTCGCCCGTCTCCAGGGT
AMod4h-R2: AGCTCCCGCAGGATCAGCGA
AMod4h-R3: CTTGAGCCCCTGGAACGCCG
AMod4h-R4: GTGGCTCGACACGTCCACCG
AMod4h-R4: CCTGCTCGGGGTCGGACAGA
AMod4h-R5: GAGTCGTCGGAGAGTCGTTC
AMod4h-R6: GAAGGGCAGAGTGATCTTCG
AMod4h-R7: TCTTCGAGTCGTCGGAGAGT
AMod4h-R8: CACGTACTCCTCGACACCAC
AMod4h-R9: GGTACATGCCCAAGGAGTTGA
AMod4h-R10: CGGGTACATGCCCAAGGAGTTGA
AMod4h-R11: TTCGAGTCGTCGGAGAGTCGTTC
3b. For M4-2f fragments:
(The following were used with XhoI-reverse)
AMod4h-F1: ACCCATCTCACCGCCACCAA
AMod4h-F2: TCACATCGGCACGAGCAACG
AMod4h-F3: GCCCTCCAAACCGCCCTCAC
AMod4h-F4: CGTTGTGGCTGGGGTCGGTC
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AMod4h-F5: CCAAACCACCTACACCCAACC
AMod4h-F6: ACACATCACCCACCACTTCA
AMod4h-F7: CAACGCACAAGACATCCAACA
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CHAPTER 4.
EXAMING SUSTRATE SELECTIVITY OF DOMAINS IN FLUVIRUCIN B1 PKS SYSTEM AND
BIOINFORMATIC ANALYSIS OF KETOSYNTHASE ON SUBSTRATE SPECIFICITY

4.1 Introduction

In the past two decades, the effort of engineering polyketide synthase has focused on the
domain manipulation of the enzyme systems, but the substrate specificities of critical domains
obstruct the engineering effort and the development of producing “un-natural” natural product.
A key step within the megasynthase is the substrate transferring of the polyketide intermediate
between an upstream ACP and a downstream KS domain (Figure 24). This process is controlled

Figure 24. Schematic diagram of intermodular transfer in modular polyketide synthases.
A polyketide intermediate is passed from an upstream ACP to a downstream KS via the
phosphopantetheine arm of holo-ACP. Often the substrate selectivity of the acceptor
KS domain determines the efficiency of this process and controls the flow of
intermediates down the assembly line. KS = ketosynthase, ACP = acyl carrier protein, AT
= acyltransferase, DH = dehydratase, ER = enoyl reductase, KR = ketoreductase.
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either via precise regulation of kinetics where ACP to KS transfer is slow compared to KR, DH, and
ER activity, or strict inherent substrate selectivity of the KS domain. For kinetically-controlled
transfer, changes in substrate functionality should not impede the overall production of
engineered products.

Conversely, those KS domains that exhibit tight substrate selectivities

may detrimentally impact product yields through greatly reduced kinetics and off-target, shunt
product formation. In these cases, a comprehensive understanding of substrate tolerance and
the ability to alternative selectivities is required for polyketide diversification. Recent insights
from KS structure determination have provided clues to potential substrate recognition motifs
within the KS active site pocket. However, these principles remain largely untested and thorough
analysis is needed to determine whether KS selectivities can be changed or broadened by proper
mutation of residues within these motifs.
Early determinations of KS substrate selectivity relied heavily on radiolabeling of
elongation products or, less commonly, the substrates themselves. 1 - 4 Small molecules were
generally delivered to the KS active site via a compatible ACP or as an N-acetylcysteimine (SNAc)
thioester, a more synthetically accessible mimic of the phosphopantetheine (Ppant) arm of holoACPs. Subsequent addition of radiolabeled extender units resulted in a single elongation event
with the KS-bound substrate. The amount of labeled product excised from the protein provided
an indirect measure of KS loading with each substrate. While very sensitive, the combination of
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high reagent cost and limited substrate availability has severely restricted the use of this method
for medium and high-throughput applications.
More recently, a number of groups have developed mass spectrometry-based techniques
for examining KS active site acylation.5-7 Many of these strategies utilize tandem proteolysis/LCMS to tease out differences in loading propensities for various substrates. Despite the many
advantages compared to radiolabeling, MS-based methods still suffer from a number of important
shortcomings. Firstly, the extremely large size of intact PKS modules generally prohibits their use
in these analyses. Smaller subunits such as KS-AT didomains are often employed as substitutes
for the full module and currently it is unclear what, if any, effect this has on substrate selectivity.
In addition, the influence of various substrates on ionization potentials, especially when
proteolysis is employed prior to analysis, has not been fully explored and may significantly impact
data interpretation and reproducibility. Finally, when particular hydrophobic groups (e.g. octyl,
napththyl, cyclohexyl) are utilized as a substantial part of a given substrate, loss of signal for
proteolysis fragments associated with KS domains is often observed, likely due to solubility issues.
In addition, our lab has developed a fluorescence transfer assay for facile determination
of KS selectivities. 8 The degree of KS acylation for a given SNAc substrate can be assayed by
introducing a fluorescent ACP, prepared from Ppant acylation with a clickable β-lactam, after
incubation of KS and substrate and monitoring ACP to KS fluorescence transfer via gel
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electrophoresis.

The amount of fluorescence transfer indicates to what extent the SNAc

compound is accepted by the KS domain (Figure 25). High KS-loading blocks subsequent
fluorescence transfer from ACP, and thus produces little to no fluorescent signal in the gel.
Alternatively, insufficient KS-acylation with a given SNAc compound leaves most KS active sites
free to accept the fluorescent substrate from ACP resulting in a bright band. This technique
provides a direct measure of KS selectivity while circumventing the limitations of radiolabeling

Figure 25. Schematic diagram of a mechanism-based, fluorescence transfer assay for KSselectivity. A given KS domain is incubated with acyl-SNAc followed by addition of fluorescently
labeled ACP. The amount of fluorescence transferred from the ACP to the KS active site
provides a direct readout of the substrate tolerance for each acyl-SNAc examined. KS =
ketosynthase, ACP = acyl carrier protein, AT = acyltransferase, SNAc = N-acetylcysteamine.
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and mass spectrometry methods described above. Most importantly, the use of mechanismbased fluorescence transfer from acyl-ACPs ensures that any fluorescence observed on the
acceptor module results solely from the KS active site and not from competing, nucleophilic
surface residues within the complex protein system.
As we unearthed a new PKS system, fluvirucin B1 synthase, an ideal system for engineering
un-natural polyketides, we were eager to figure out the substrate specificity within the domains
of fluvirucin B1 PKS in order to overcome the engineering hurdle that we describe above. Herein,
we described our finding for FluAT selectivity and FluKS specificity, and also provided our
bioinformatic analysis of FluKS for future engineering purposes (see section 5.3.1).

4.2 Results and Discussions

4.2.1 Cloning and Protein Expression of KSATs and ACPs

To determine the selectivities of the domains in this assembly line, appropriate primers
were designed for the cloning of all KS-AT didomains within fluvirucin B1 PKS. However, even
though all five KSATs were cloned out without any difficulties, only KSAT of modules 1, 3 and 5
were successfully expressed in E. coli BL21 strain. On the contrary, ACPs of all the five modules
were successfully cloned and expressed in E. coli BAP1 strain in order to harvest the fully
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functional ACPs purified with the Ppant group. In addition, the terminal TE domain were also
cloned and overexpressed in BL21 (Figure 26).

Figure 26. SDS PAGE analysis of fluvirucin B1 PKS domains overexpressed in E. coli following NiNTA affinity purification. Lanes are marked with corresponding protein. Molecular weights are
indicated for each gel. (A) Flu-KSAT didomains (B) Flu ACP domains (C) Flu TE domain.

4.2.2 Examine the AT Selectivities.

To examine the domain selectivities, we began synthesizing substrate analogs to probe
FluATs. We are convinced that not only the information could be useful to confirm the result from
our bioinformatic analysis, but also we could establish the methodology we deployed for other
domains as well in terms of using LC-MS.
As we alluded in chapter 2, using the SEARCHPKS program developed by Mohanty and coworkers9, modules 2 and 4 showed high sequence similarity with malonyl-specific AT domains,
while module 3 was predicted to utilize methylmalonyl-CoA. Modules 1 and 5 returned a single
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hit for ethylmalonate specificity amidst several methylmalonylspecific AT domains. To
experimentally verify the putative AT selectivities for modules 1, 3, and 5, ketosynthaseacyltransferase (KSAT) didomains were cloned from these modules along with the corresponding
ACP domains. Each KSAT didomain was mixed with ACP from the same module followed by
introduction of either malonyl-, methylmalonyl-, or ethylmalonyl-N-acetylcysteamine (SNAc)

Figure 27. Schematic diagram of and observed results for the AT substrate selectivity studies
of modules 1, 3, and 5. Red checks indicate that the substrate shown on the left is transferred
from the indicated AT to the ACP domain, whereas a black X indicates that no substrate
transfer was observed. See Supporng Informaon for raw LC−MS data. FluATX = fluvirucin
AT domain from module X.
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thioesters. Following 30 min of incubation with each substrate, samples were trypsinized, and
the extent of AT to ACP transfer for each extender unit was analyzed by LC−MS (Figure 27).
Gratifyingly, experimentally determined AT selectivities for modules 1, 3, and 5 were consistent
with those suggested by sequence homology. It is important to note that no direct acylation of
ACP was observed with any of the extender units, indicating that AT to ACP transfer is the sole
mechanism for formation of the acylated ACP (data not shown).

4.2.3 FluKS Substrate Selectivity

As we summarized before, the capability of KS domain accepting different substrates
could potentially increase product yields in polyketide engineering. On the way in characterizing
our unique fluvirucin B1 PKS, one of our objectives is to test the tolerance of KSs by applying the
technique we developed and described above. We believed that gaining the information of the
KS selectivity would provide the reference of altered β-functionalities and insight for better
polyketide engineering. Based on our current bioinformatic analysis and prediction, FluKSs only
have two different kind preferences of β-substituents: one is a methylene and the other a βhydroxyl substituent, we will focus on Flu KS3 which only accepts a β-hydroxy acyl group of all the
KS domains.
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To examine the selectivity in FluKS3 for the hydroxyl group stereo-configuration and
provide further evidence connecting this PKS with fluvirucin B1 production, tandem
proteolysis/LC−MS was again employed. SNAc thioesters of both enantiomers of 3hydroxybutyrate were prepared and introduced separately to KSAT3. Following 1 h of incubation,
samples were trypsinized, and KS-acylaon was observed via LC−MS analysis. As predicted from
the fluvirucin B1 structure, only the (S)-3-hydroxybutyryl-SNAc compound, which places the
hydroxyl group in the same three-dimensional orientation as the ring hydroxyl of the final
product, was accepted by the module 3 KS domain (Figure 28). Very little to no KS-acylation with
the (R)-isomer was observed.

Figure 28. LC−MS data for module 3 KS-acylation with (R)-3-hydroxybutyryl-SNAc (top) and (S)3-hydroxybutyryl-SNAc (bottom). Only the (S)-isomer is accepted by module 3 KS as is expected
from the fluvirucin B1 structure. Peaks are labeled with the corresponding acylated or
unacylated KSAT3 didomain. All peaks are m/z = +2.
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The mechanism based fluorescence transfer assay that was developed in our lab was also
used to examine the stereochemical preference of Flu KS3. The fluorescent ACP was prepared by
incubating holo Flu-ACP3 with N-propargyloxycarbonyl-β-lactam for an hour. The acylated ACP
was then “clicked” with rhodamine azide. The KSAT3 was preloaded with the substrates for an
hour followed by addition of the fluorescent ACP for 30 minutes and SDS PAGE analysis of each
reaction. The bright KSAT3 bands observed for the (R) - stereoisomer indicates that there was
little to no KS acylation. The weak fluorescent band observed in the (S) - stereoisomer lane is an
indication of efficient KS acylation and confirms the earlier LC-MS results obtained (Figure 29).

Figure 29. Mechanism based fluorescence transfer assay for Flu KSAT 3 substrate specificity
towards (R)-and (S)-3-hydroxy butyryl SNAc
Subsequently, we prepared a small panel (Figure 30) of SNAc thioesters for a preliminary
test on FluKS3. They incorporate different variations of hydroxyl, enoyl and fully reduced carbon
at the beta position. This panel is a good starting point to investigate the preferences of KS for

79

variation of functionalities at the
beta position and be used further
as a framework for testing the
other four KSs in this PKS system.
By following the same procedure
for LC-MS methodology, we found

Figure 30. A panel of substrate analogs for KS selectivity

that FluKS3 prefer not only the (S)isomer but also the β-keto thioester probe, and that FluKS3 slightly interacts with the βmethlyene analog but does not accept any other substrates (data not shown). In sum, we suggest
these preliminary experiments will provide some insight into the extent and contrasts of tolerance
exhibited within other KSs.

4.3 Experimental Procedures

4.3.1 Cloning of KSAT and ACP Domains of Fluvirucin B1 PKS

The DNA sequence encoding Flu-KSAT1 was amplified from pTL-A01 by the PCR protocol
described for pre-module 2. Flu-KSAT1 was constructed as an NheI-EcoRI fragment by using
following primers, pTL-KSAT1-F: TTTTTTGCTAGCGAGCCCATCGCGATCGTC and pTL-KSAT1-R:
AAAAAAGAATTCTGGTCCACGGCGGCCTGG. This NheI-EcoRI fragment was cloned into the pET21b
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expression vector to yield plasmid pTL-KSAT1. The DNA sequence encoding Flu-KSAT3, Flu-KSAT5
and Flu-ACP1, Flu-ACP3, Flu-ACP5 were cloned similarly by the corresonding templates the
corresponding primers as follows, pTL-KSAT2-F: TTTTTTGCTAGCGAGCCGATCGCGATCGTG
pTL-KSAT2-R: AAAAAAGAATTCAGGGAGGACAGGGCGGGAAG
pTL-KSAT3-F1: TTTTTTGCTAGCATGGCCACTGACGACAAG,
pTL-KSAT3-R1: AAAAAAGAATTCGGATCCACCCGGGTCAGG;
pTL-KSAT4-F: TTTTTTGCTAGCATCGGGGAGCCGATCGCGATC,
pTL-KSAT4-R: AAAAAAGAATTCTGGTCCGCGGGGGCCTGGC;
pTL-KSAT5-F1: TTTTTTGCTAGCATGGCTGACGAAGAGAAG,
pTL-KSAT5-R2: AAAAAAGAATTCTGATCCACCCGAGCCTG;
pTL-ACP1-F: TTTTTTGCTAGCCTGACCGGACTACCGGCG,
pTL-ACP1-R: AAAAAAGAATTCGTGACACGCTGGAGCAG;
pTL-ACP2-F: TTTTTTGCTAGCCTCGCGGAGCTGCCGCCGGCC,
pTL-ACP2-R: AAAAAAGAATTCGTGAGCCTGTCCTGGACGAAC;
pTL-ACP3-F:TTTTTTGCTAGCCTGACCGGCCTGCCCGCG,
pTL-ACP3-R: AAAAAAGAATTCGTGACACGCTGGAGCAG;
pTL-ACP4-F: TTTTTTGCTAGCCTGGCCGGGCTGCCCCCG
pTL-ACP4-R: AAAAAAGAATTCAGGAGCTGGCTCCCCATGTA
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pTL-ACP5-F: TTTTTTGCTAGCCTGGCCGGGCTGTCG,
pTL-ACP5-R:AAAAAAGAATTCGCGATCTCCTCCGCCAG
The resulting plasmids for Flu-KSATs (pTL-KSAT1 to 5) were transformed into BL21(DE3).
The plasmids constructed for Flu-ACPs (pTL-ACP1 to 5) were introduced into BAP1.

4.3.2 General Method for Preparation of All N-Acetylcysteamine (SNAc) Thioester Derivatives

To a solution of triethylamine (2.80 mmol) in dichloromethane (10 mL) was added the
appropriate acid (1.40 mmol), (3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.40
mmol), 1-hydroxybenzotriazole (HOBt) (1.40 mmol) and N-acetylcysteamine (SNAc) (1.35 mmol)
under argon. The reaction mixture was stirred overnight. The organic layer was washed with
saturated NaHCO3 solution, 0.1 N HCl solution and brine. It was then dried over anhydrous sodium
sulfate, concentrated under vacuum, and purified by flash column to provide the final product in
pure form.
Butyroyl SNAc
Using butyric acid, the general procedure was followed
1H

NMR (400 MHz, CDCl3) δ ppm 0.92-0.96(t, J=, 3H), 1.67-1.69(m, 2H), 1.95(s, 3H), 2.52-

2.56(t,2H),2.99-3.00(t, 2H), 3.40-3.42(q, 2H), 6.12(s, 1H).
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13C

NMR (400 MHz, CDCl3) δ ppm 11.54, 17.17, 21.27, 26.55, 37.64, 44.12, 168.64, 197.97.

IR: ν 3291.13, 2967.08, 1651.12, 1547.47, 1436.23, 1370.50,1284.55, 1112.64, 988.76, 905.33,
723.31 cm−1
LC-MS [M+H]+ = 190.0.
Trans-2-butenoyl SNAc
Using crotonic acid, the general procedure was followed.
1H

NMR (400 MHz, CDCl3) δ 1.86 (dd, 3 H), 1.93 (s, 3 H), 3.05 (t, 2 H), 3.44 (dt, 2 H), 6.11 (dq, 1H),

6.21 (s, 1 H), 6.90 (dq, 1 H);
13C

NMR (400 MHz, CDCl3) δ 17.9, 23.1, 28.1, 39.8; 129.8, 141.7, 170.3;

LC-MS [M+H] 188.2
(R)-3-hydroxy butyroyl SNAc
Using (R)-hydroxy butyric acid, general procedure was followed
1H

NMR (400 MHz, CH3Cl-d) δ ppm 1.33 (3 H, d, J=6.82 Hz), 1.98 (3 H, s), 2.65 - 2.76 (2 H, m), 2.78

- 2.82 (1 H, d), 3.04 - 3.10 (2 H, t), 3.27 - 3.31 (1 H, m), 3.42-3.46(3H, q), 6.36 (1 H, br. s.)
13C NMR (400 MHz, CH3Cl -d) δ ppm 19.76, 21.35, 26.95, 28.50, 34.57, 37.48, 49.19, 168.60, 195.73

LC-MS [M+H] for C8H15NO3S calcd 206.1 found 206.1
(S)-3-hydroxy butyroyl SNAc
Using (S)-hydroxy butyric acid, general procedure was followed.

83

1H

NMR (400 MHz, CH3Cl-d) δ ppm 1.33 (3 H, d, J=6.82 Hz), 1.98 (3 H, s), 2.65 - 2.76 (2 H, m), 2.78

- 2.82 (1 H, d), 3.04 - 3.10 (2 H, t), 3.27 - 3.31 (1 H, m), 3.42-3.46(3H, q), 6.36 (1 H, br. s.)
13C NMR (101 MHz, CH3Cl -d) δ ppm 19.76, 21.35, 26.95, 28.50, 34.57, 37.48, 49.19, 168.60, 195.73

LRMS [M+H] for C8H15NO3S calcd 206.1 found 206.1
β-keto butyroyl SNAc
To a solution of meldrum acid (10mmol) in dichloromethane at 0oC was added pyridine
(21mmol). Acetyl chloride (12mmol) was added dropwise to the mixture, with the solution turning
deep red. The reaction was stirred for an hour at 0oC and then warmed to room temperature
overnight. Mixture was washed 3X with 0.1M HCl, dred with sodium sulfate and concentrated to
yield the acetylated meldrum acid as a dark orange solid in 84% yield. 8mmol of this acetylated
meldrum acid and 7.7mmol of N-acetylated cysteamine (SNAc) were refluxed in toluene for
5hours. After the mixture was cooled to room temperature, it was concentrated to yield titled
compound in 78% yield.

4.3.3 Synthesis of malonyl and substituted malonyl SNAc thioesters

These syntheses we carried out using established procedures25. A general outline follows:
To a solution of appropriate malonic or substituted malonic acid (1eq) in dry THF (5mL), was added
pyridine (2.2eq) and t-butanol (1.8eq). The solution was cooled to 0°C. Methanesulfonyl chloride
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(1.05eq) was then added dropwise over a 10 minute period. The reaction mixture was warmed to
room temperature and stirred for 3 hours. The mixture was filtered and the resulting filtrate
diluted with water. The pH was adjusted to ~12 and washed 3X with dichloromethane. The
aqueous layer was acidified (pH ~2), extracted 3X with dichloromethane and dried with sodium
sulfate. The product was then coupled to SNAc via EDC coupling. In an RB flask, the acid (1.1eq)
was dissolved in dichloromethane. EDCI (1.2eq), DMAP (0.02eq) and SNAc (1eq) were then added
and reaction stirred at room temperature overnight. The mixture was diluted with water and
dichloromethane. The organic layer was washed with NH4Cl, NaHCO3, and brine, and then dried
with Na2SO4. Concentration in vacuo yielded the expected product. The product was dissolved in
TFA at 0°C. After stirring at 0°C for 24 hours, TFA was evaporated. The product was diluted with
diethyl ether and concentrated. This was repeated three times. The crude product was purified
by chromatography to yield the titled compound.
Malonyl SNAc thioester (pale white solid) (70% yield)
1H

NMR (400 MHz, DMSO-d6) δ ppm 1.79 (br. s., 3 H), 2.95 (br. s., 2 H), 3.18 (br. s., 2 H), 3.65 (br.

s., 2 H), 8.06 (br. s., 1 H)
13C

NMR (400 MHz, DMSO-d6) δ ppm 21.04, 27.06, 36.57, 48.21, 165.97, 167.91, 190.24

LRMS [M+H] for C7H11NO4S calcd 206.0 found 206.1
Methyl Malonyl SNAc thioester (pale white solid) (63% yield)
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1H

NMR (400 MHz, CH3Cl -d) δ ppm 1.44 (3 H, d, J=7.07 Hz), 1.99 (3 H, s), 3.06-3.17 (2 H, m), 3.40

- 3.52 (2 H, m), 3.63 - 3.77 (1 H, m), 6.71 (1 H, t, J=5.56 Hz), 10.35 (1 H, br. s.)
13C

NMR (400 MHz, CHLOROFORM-d) ppm 12.13, 20.74, 26.59, 37.64, 52.07, 170.24, 170.59,

194.96
LRMS [M+H] for C8H13NO4S calcd 220.1 found 220.1
Ethyl malonyl SNAc thioester (pale yellow solid) (51% yield)
1H

NMR (400 MHz, CH3Cl -d) δ ppm 1.01 - 1.06 (2 H, m), 2.01 (3 H, s), 3.05 (1 H, dd, J=13.26, 6.69

Hz), 3.11 - 3.22 (1 H, m), 3.37 (1 H, t, J=7.20 Hz), 3.48 ( 2H, q, J=5.89 Hz), 3.56 (1 H, t, J=7.45 Hz),
6.59 (1H, br. s.), 11.53 (1H, br. s.)
13C

NMR (101 MHz, CH3Cl -d) δ ppm 9.83, 20.63, 20.98, 26.62, 37.73, 51.02, 59.44, 170.96, 172.31,

194.21
LRMS [M+H] for C9H15NO4S calcd 234.1 found 234.1

4.3.4 ACP Acylation by AT

To a mixture of ACP (50 μM) and KS-AT (2 μM) in 100mM pH 7.0 phosphate buffer (50 μL
total volume) containing 2.5 mM TCEP at 4°C was added appropriate SNAc thioester substrate
(500 μM) . The mixture was incubated 4°C for 30 min to achieve AT assisted acylation of the ACP.
Sequence grade modified trypsin was added to prepare samples with final ration trypsin:ACP to
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be 1:10 (w/w). The mixture was incubated for 60 min at 37°C. Digestion was quenched by addition
of equal volume of 10% formic acid. Digests were stored at -80°C until analysis.

4.3.5 KSAT3 Loading

To a mixture of Flu-KSAT3 (25 μM) in 100 mM pH 7.0 phosphate buffer (50 μL total
volume) containing 2.5 mM TCEP at 4°C was added appropriate SNAc thioester substrate (5mM).
The mixture was incubated 4°C for 60 min to achieve KS acylation. Sequence grade modified
trypsin was added to prepare samples with final ratio trypsin:ACP to be 1:10 (w/w). The mixture
was incubated for 60 min at 37°C. Digestion was quenched by addition of equal volume of 10%
formic acid. Digests were stored at -80°C until analysis.

4.3.6 Fluorescence Transfer Assay

Unless otherwise stated, phosphate buffer refers to 100 mM, pH 7.0 phosphate. Flu-ACP3
(25 μM total protein) was equilibrated at ambient temperature for 15 min in phosphate buffer
containing 2.5 mM TCEP. Poc β-lactam (10× with respect to total ACP concentration) was added
and the mixture was equilibrated at ambient temperature for 45 min. Rhodamine Azide (2× with
respect to Poc β-lactam), sodium ascorbate (1 mM), and copper (II) sulfate (1 mM) were added to
ACP samples which had been labeled with Poc β-lactam. The reaction was performed at ambient
temperature for 45 min. To remove excess Poc β-lactam and Rhodamine Azide, the mixture was
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loaded into a 3 kDa NMW concentrator and the volume reduced to 100 μL by spinning in a
centrifuge cooled to 4 °C. The mixture was diluted to 500 μL with phosphate buffer, and then
concentrated to 100 μL again. This process was repeated a total of 5 times. Protein was removed
from the concentrator by inverting it and spinning. For transfer of the fluorescent product, [FluKSAT3] was pre-treated with respective SNAc (2.5 mM) derivatives for 1 h. This mixture was
introduced to filtered acyl-ACP3 and incubated for 30 min. The [Flu-KSAT3] control was executed
under the same acylation and click conditions as in other samples but without the SNAc derivative
and therefore represents full acyl transfer.

4.3.7 Chromophore Attachment

The reaction was carried out at 25 μL, final concentrations reported. Rhodamine Azide,
(2× with respect to Poc β-lactam), sodium ascorbate (1 mM), and copper (II) sulfate (1 mM) were
added to ACP samples which had been labeled with Poc β-lactam. The reaction was performed at
ambient temperature for 45 min.

4.3.8 Gel Assay

Labeled samples were diluted to 20 μL with gel-loading buffer. Proteins were separated
using a 4–20% gradient HEPES-PAGE gel (100 V, 50 mA, 70 min). Gels were developed in 10%
acetic acid to visualize Rhodamine Azide. Labeled proteins were imaged on a UV-transilluminator.
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Total protein was stained using Coomassie stain.trypsin was added to prepare samples with final
ration trypsin:ACP to be 1:10 (w/w). The mixture was incubated for 60 min at 37°C. Digestion was
quenched by addition of equal volume of 10% formic acid. Digests were stored at -80°C until
analysis.
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CHAPTER 5.
SUMMARY AND FUTURE DIRECTIONS

5.1 Discussion

Fluvirucin B1 is a relatively simple natural product stemming from a rather complex set of
biosynthetic transformations. Despite the diminutive size of the PKS responsible for its production
in A. vulgaris, each round of elongation and subsequent β-carbon tailoring requires extensive
manipulation of functionality. Four of the five putative extender modules bear the full compliment
of tailoring domains, meaning that at each of these positions within the assembly, keto-, hydroxyl, and olefin-containing intermediates are generated enroute to the fully saturated product, similar
to mammalian fatty acid synthase. We have hypothesized that this type of module composition
will afford the highest engineering potential as product diversification can be achieved without
the need for incorporation of heterologous domains. In other words, one can potentially access
each of the aforementioned functionalities by simple active site mutagenesis of KR, DH, and ER
domains leaving the highly evolved protein−protein communication and recognition interfaces in
their native states. This is in stark contrast to more popular assemblies such as 6deoxyerythronolide B synthase (DEBS), where nearly all of the extender modules contain, at most,
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a KR domain, where only ketone functionalities are accessible via similar active site mutagenesis
strategies.1 For this reason, we were eager to uncover the biosynthetic origins of fluvirucin B1.
As predicted, the fluvirucin B1 polyketide synthase consists of 5 extender modules flanked
by an N-terminal loading ACP and C-terminal TE domain. All but one of the extender modules
contains a KR, DH, and ER domain in addition to the required KS, AT, and ACP leading to the
relatively un-functionalized nature of the macrolactam product. On the basis of this arrangement
of composition of modules, β-alanine is expected to serve as the starter unit for fluvirucin B1
biosynthesis. As strong evidence for this hypothesis, fluI, which putatively encodes for a PLPdependent decarboxylase, displays high homology with both vinO from the vicenistatin PKS
cluster and azicN from the azicemicin PKS cluster.2,3 The former is responsible for decarboxylation
of 3-methylaspartate, while the latter decarboxylates aspartic acid itself, leading to 3-methyl-βalanine and β-alanine, respectively. While further studies are needed to confirm the starter unit
identity for fluvirucin B1 biosynthesis, this data strongly suggests a role for β-alanine in the early
stages of macrolactam construction.
As alluded to above, thorough analysis of the protein sequences for each module reveals
an intriguing trend with implications as to the evolutionary origins of these PKS components.
Pairwise alignments between fluvirucin B1 PKS modules 1, 3, and 5 yield protein sequence
identities ranging from 75% to 81% (Table 7).

92

Table 7. Sequence comparison results for Flu modules and DEBS module 4
Sequence
comparison

FluMod1

FluMod2

FluMod3

FluMod4

FluMod5

(Identities/
Similarities)

DEBS
Mod4

FluMod1

100%/100%

61%/72%

81%/86%

60%/70%

80%/86%

49%/61%

FluMod2

61%/72%

100%/100%

64%/75%

95%/96%

64%/75%

58%/72%

FluMod3

81%/86%

64%/75%

100%/100%

63%/73%

74%/82%

50%/63%

FluMod4

60%/70%

94%/96%

63%/73%

100%/100%

60%/70%

41%/56%

FluMod5

80%/86%

64%/75%

75%/82%

60%/70%

100%/100%

49%/62%

*All sequence comparison done by BLAST of NCBI website. All modules listed in the column are
used as query, and the modules listed in the row are used as subject.
**In cases where the compared modules are of dramatically different sizes (i.e Flu Mod 1 vs. Flu
Mod2) identities are related only to the KS-AT regions (regions of max identity) of the modules.
Similarly, modules 2 and 4 show 94% sequence identity. When analogous alignments are
executed between these two groups (e.g., module 1 vs module 2), more typical identities ranging
from 60% to 64% are observed. By comparison, sequence identities between modules from the
well characterized DEBS assembly as well as between DEBS modules and fluvirucin PKS modules
fall in the more modest 40−60% range (Table 8). The similarities between fluvirucin B1 synthase
modules might suggest independent ancestry for modules 1, 3, and 5 versus 2 and 4. It is
important to note that the remarkable sequence identities observed within these two groups
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occur despite the fact that each module both accepts and processes appreciably different
polyketide intermediates.
Table 8. Sequence Comparison Results for DEBS Modules
Sequence
comparison
(Identities/
Similarities)

DEBS
Mod1

DEBS
Mod2

DEBS
Mod3

DEBS
Mod4

DEBS
Mod5

DEBS
Mod6

DEBS
Mod1

100%/100%

49%/60%

48%/61%

56%/68%

49%/61%

59%/68%

DEBS
Mod2

(49%/60%)

100%/100%

48%/59%

52%/64%

50%/61%

49%/61%

DEBS
Mod3

(48%/61%)

(48%/59%)

100%/100%

56%/69%

48%/62%

51%/64%

DEBS
Mod4

(56%/68%)

(52%/64%)

(56%/69%)

100%/100%

57%/68%

(52%/64%)

DEBS
Mod5

(49%/61%)

(50%/61%)

(48%/62%)

57%/69%

100%/100%

(50%/61%)

DEBS
Mod6

(59%/68%)

(49%/61%)

(51%/64%),

52%/64%

50%/61%

100%/100%

*Comparison results in parentheses are results from reverse query/subject pairs.
Another interesting aspect of the fluvirucin B1 synthase involves the TE domain. Most
macrocycle-forming thioesterases bear a conserved serine residue charged with accepting the
fully mature, linear polyketide intermediate from an immediately upstream ACP followed by
cyclization and product release.
The fluvirucin B1 TE domain instead uses a cysteine active site for this task. This type of
serine to cysteine substitution has been observed in other PKS systems, prompting speculation as
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to possible divergent evolutionary origins between these two active site arrangements. 4 - 6
Although beyond the scope of this thesis, this somewhat unique feature of the fluvirucin B1
synthase should provide additional insights into any kinetic consequences of this switch and thus
warrants further study.

5.2 Conclusions

In summary, we have identified and characterized the putative PKS genes associated with
fluvirucin B1 aglycone biosynthesis in A. vulgaris. The number and composition of modules as well
as predicted AT specificities are consistent with the fluvirucin B1 structure. The abundance of
tailoring domains within the assembly is expected to provide increased engineering potential,
through straightforward active site mutagenesis. Reconstitution of biosynthesis in a more
workable host will greatly facilitate these studies and efforts to do so are currently underway in
our laboratory.

5.3 Future Directions

5.3.1 Native Ketosynthase Selectivities in the Fluvirucin PKS

As alluded to above, our lab has recently developed a mechanism-based fluorescence
transfer assay for examining KS substrate tolerance (Figure 25, chapter 4). This method stems
from previous work using b-lactones and b-lactams as site-specific, electrophilic partners for the
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Ppant thiol of holo-ACPs. 7 - 8 The thioester-ACP resulting from incubation of holo-ACP with a
propargyloxycarbonyl (Poc)-activated b-lactam was shown to be competitive with traditional
SNAc thioesters for KS acylation. Based on these results, it occurred to us that fluorescent
thioester-ACPs, derived from an alkyne-bearing β-lactam, coupled with acyl-SNAc compounds,
could provide a straightforward means of examining KS selectivity in whole PKS modules.
We expect that substrate recognition in KS domains arises primarily from functionality
near the thioester bond. Mutational inactivation of KR, DH, and ER domains will afford polyketide
intermediates with modification at the β-position and thus, this position is the most logical place
to begin our analysis of substrate recognition. A panel of SNAc thioesters bearing ketone,
hydroxyl, olefin, and methylene β-functionalities along with the appropriate hydrogen, methyl,
and ethyl α-functionalities will be prepared via established methods (Error! Reference source not
found.). 9 An added benefit of this analysis is that hydroxyl-group stereoselectivities, not
immediately obvious from the products accepted by modules 2, 4, and 5, will be established for
future studies utilizing the full fluvirucin PKS. KS domains from modules 2, 3, 4, and 5 will be
incubated with SNAc compounds containing each β-functionality and the appropriate αfunctionality, as determined by the immediately upstream AT domain, to establish a substrate
scope for each. In the case of inconclusive or irregular observations in the data, traditional LC-MS
techniques will be used for further confirmation.
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Figure 31. Panel of SNAc thioesters for determination of KS substrate selectivities in the
fluvirucin PKS.

From these data, we expect two principal outcomes: 1) KS-domains utilizing purely
kinetic-control for transfer of the proper intermediate will show little to no selection for a
particular substrate and, 2) those evolved to only accept a certain substrate will exhibit the
opposite response to non-native functionality. Domains that fall into the first category will require
no alteration and can be used directly for fluvirucin analog production described in section 5.3.3.
Conversely, for situations where strict substrate selectivities or a combination of both outcomes
is observed, we will attempt to alter or broaden the substrate scope using targeted mutagenesis
of residues located in a variable region of the KS active site pocket as detailed in section 5.3.2.
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5.3.2 Altered Ketosynthase Selectivities via Mutation of Active Site Pocket Residues

Recent crystallographic data for the KS domains of DEBS modules 3 and 5 has provided
new insights into substrate recognition interfaces surrounding the active site.10 Most of the deep
KS active site pocket is highly conserved among modular PKSs. However, as Khosla and coworkers
observed upon modeling a triketide and pentaketide substrate into the active site of DEBS module
3 and 5 KS domains, respectively, there exists a small variable region within the pocket that may
allow the KS to distinguish certain substrate functionalities and sizes (Figure 32. Crystal structure
of the DEBS module 3 KS
active site pocket (PDB:
2QO3).

Active

site

cysteine indicated by a
green sphere. The four
loop residues thought to
play a role in substrate
Figure 32. Crystal structure of the DEBS module 3 KS active site
pocket (PDB: 2QO3). Active site cysteine indicated by a green sphere. recognition are labeled
The four loop residues thought to play a role in substrate recognition
accordingly.

are labeled accordingly.

).

This

hypothesis is yet untested
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and the fluvirucin PKS KS domains exhibiting strict substrate selectivities from section 5.3.1 will
offer the ideal platform for experimental investigation of the model.
Motivated by this
observation,

we

were

interested in whether any
distinct sequence patterns
could be detected within this
region that might lead to
selectivity for each common
polyketide β -functionality.
Separate alignments were Figure 33. Consensus sequences for each of the four KS active
site pocket residues of interest (see Figure 32. Crystal structure
executed for KS domains of the DEBS module 3 KS active site pocket (PDB: 2QO3). Active
site cysteine indicated by a green sphere. The four loop residues
falling into one of four
categories:

those

that

thought to play a role in substrate recognition are labeled
accordingly.

).

Molecules on the left indicate which β-

functionality is accepted by the KS domain from an upstream
natively

accept

an ACP. Each consensus sequence was determined by alignment of
at least 25 individual sequences. The more hydrophobic olefin

intermediate bearing a 1) and methylene functionalities generally coincide with more
hydrophobic residues at positions 1 and 2 while ketone and
ketone, 2) hydroxyl, 3) olefin
or, 4) methylene at the β-

hydroxyl groups tend to prefer hydrophilic residues at these
positions.
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position from an upstream ACP. Consensus sequences derived from this data revealed some
intriguing trends (Figure 33. Consensus sequences for each of the four KS active site pocket
residues of interest (see Figure 32. Crystal structure of the DEBS module 3 KS active site pocket
(PDB: 2QO3). Active site cysteine indicated by a green sphere. The four loop residues thought to
play a role in substrate recognition are labeled accordingly. ). Molecules on the left indicate
which β-functionality is accepted by the KS domain from an upstream ACP. Each consensus
sequence was determined by alignment of at least 25 individual sequences.

The more

hydrophobic olefin and methylene functionalities generally coincide with more hydrophobic
residues at positions 1 and 2 while ketone and hydroxyl groups tend to prefer hydrophilic residues
at these positions). Firstly, it is not immediately obvious that this region of the active site pocket
is able to distinguish between β-keto and β-hydroxyl functionalities. In contrast, positions 1 and
2 may play a critical role in selecting between hydrophobic and hydrophilic groups. For the more
polar ketone and hydroxyl groups, these two positions are dominated by hydrophilic residues
capable of hydrogen bonding while KS domains that natively accept olefin and methylene
functionalities generally possess more hydrophobic amino acids at these positions. For example,
close examination of these residues in fluvirucin module 3, which accepts a β-hydroxyl group, and
module 5, which accepts a β-methylene, reveals a similar trend. Module 3 KS bears a glycine at
position 1 and threonine at position 2 while module 5 KS contains an alanine at position 1 and a
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phenylalanine at position 2. If either of these KS domains exhibit strict selection for its native
substrate, introducing more hydrophobicity to module 3 and more hydrophilicity to module 5 may
serve to reverse its substrate tolerances.
In a broader sense, the consensus sequences for each β-functionality will be introduced,
via site-directed mutagenesis, to each fluvirucin KS domain that displays high substrate selectivity
from section 5.3.1. The impact of these mutations will be readily observed using our fluorescence
transfer assay. Any changes to the fluorescence pattern between the unmodified and mutated
KS domains will be confirmed by tandem proteolysis-LCMS. Mutant KS domains with altered or
relaxed substrate selectivity relative to wild-type will join the kinetically-controlled KS domains
for production of novel fluvirucin analogs.
If grafting consensus sequences onto the selective KS domains results in little change to
substrate tolerances, alternative strategies are in place to further explore the role of this pocket
region in substrate recognition. The 20+ sequences used to generate each consensus sequence
above come from a wide variety of PKS systems at vastly different positions along each assembly
line. Therefore, it may be worth adopting narrower search criteria for modification of KSselectivities. In lieu of consensus sequences, we will search within each subset of available
sequences for KS domains that natively accept substrates with the highest similarities, in terms of
length, α-functionality, and more distal functionality to the natural fluvirucin substrates. For
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instance, the natural substrate of DEBS module 4 is a tetraketide containing α-methyl and β-keto
functionalities, and a β-keto form of the fluvirucin module 4 substrate would bear significant
resemblance to this. Therefore, the DEBS module 4 active site pocket sequence (MNGQ), which
has little in common with the fluvirucin module 4 sequence (GTQT), is a potential alternative to
the consensus sequence (TNGQ). Given the projected flexibility of the loop which harbors the
target residues and sequence variability observed for each type of β-functionality, it is probable
that even minor changes to this region will have a dramatic impact on KS-selectivities.
As a second alternative strategy, we will broaden our pursuit using saturation
mutagenesis to explore full sequence variation at positions 1 and 2 of the target active site pocket
region. The resulting mutant KS domains will be expressed and subsequently bound to Ni-NTA
beads or functionalized plates. After thorough washing, the bound KS domain will be incubated
with substrate(s) bearing the desired β -functionalities followed by addition of an untagged,
fluorescent ACP. The mutant KS domains will then be eluted from the Ni-NTA and the degree of
ACP to KS fluorescence transfer will be determined by PAGE analysis. Gels will then be stained to
confirm that any lack of fluorescence is the result of active site acylation with substrate and not
poor expression of the KS domain. As above, any mutant KS domains that show altered or
broadened substrate tolerance will be utilized in section 5.3.3 for optimization of fluvirucin analog
production. Together with the more targeted strategies described above, we are well positioned
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to clearly define a role for these residues in substrate recognition which will aid in future
exploration of KS active site pockets well beyond the fluvirucin system.

5.3.3 Macrolactam Production from Engineered Fluvirucin PKS

In order to reconstitute the biosynthesis of fluvirucin B1 aglycone and further to produce
its analogs, we will utilize the constructs and information generated from native KSATs
selectivities (section 5.3.1) and bioinformatic analyses (section 5.3.2) to systematically examine
the relative contributions of KS substrate selectivity and disruption of protein-protein interactions
on fluvirucin analog production. We envision three possible outcomes from the work described
in previous chapters. Firstly, it may be the case that all KS domains in the fluvirucin PKS are
kinetically controlled, in which case broad substrate tolerance will be observed across the board.
In the unlikely event that this is the case, we still plan to explore the role of active site pocket
residues as described in section 5.3.2. Any changes to substrate selectivity arising from these
studies will provide critical insight for other PKSs where KS substrate selectivity is more tightly
regulated. Should we instead observe the opposite and equally unlikely case where all KS domains
exhibit high selectivity for a particular substrate, we stand to gain maximal insight as to the role
played by the aforementioned active site pocket residues in substrate recognition. While we are
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prepared for either of these two extremes, the most likely scenario for chain transfer in the
fluvirucin PKS involves a combination of these mechanisms.
In any case, we have reconstructed the full fluvirucin PKS on three separate plasmids with
unique resistance markers. The first two plasmids contain fluA (modules 1 and 2, Figure 34) and
fluB (modules 3 and 4, Figure 35) while the third harbors fluC (module 5, Figure 36) and the genes
necessary for methylmalonyl-CoA production (Figure 36). Using these three constructs, we will
attempt to reconstitute the fluvirucin PKS pathway in E. coli. This versatile host has been
instrumental in much of the DEBS work and has proved quite tolerant of fluvirucin-related genes
in our preliminary work with this system. Despite the many advantages of using E. coli for
fluvirucin production, this host does have some limitations and a plan to tackle these potential
issues is essential.
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Figure 34. The plasmid map of pTL-F01b
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Figure 35. The plasmid map of pTL-F02
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Figure 36. The plasmid map of pTL-F03p

5.3.3.1 Reconstituting Fluvirucin B1 Aglycone Production in E. Coli

The most challenging part of using a heterologous host for fluvirucin production will be
rendering the PKS functional. This system utilizes methylmalonyl- and ethylmalonyl-CoA as
extender units, both of which are produced at very low levels, if at all, in E. coli. Luckily, the issue
of methylmalonyl-CoA production has previously been solved for the DEBS system via
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introduction of propionyl-CoA carboxylase (PCC) and related genes. 11 - 12 We will rely on this
technique for the fluvirucin PKS, but an equivalent means of ethylmalonyl-CoA generation will
likely necessitate further engineering of the host. We have devised several complementary
strategies for tackling this issue including (1) exploiting the relaxed substrate tolerance of PCC,
and (2) introduction of crotonyl-CoA carboxylase/reductase (CCR).
Propionyl-CoA Carboxylase: As the most straightforward of these potential solutions, we
may be able to simply use the same enzymes responsible for methylmalonyl-CoA production. It
has been observed that PCC has moderately relaxed substrate selectivity and will catalyze, albeit
with lower efficiency, carboxylation of butyryl-CoA. 13 , 14 We will attempt to generate both
methylmalonyl- and ethylmalonyl-CoA by addition of propionate and butyrate, respectively, to
our engineered E. coli cultures. Since propionate is converted faster than butyrate, we plan to
add the latter in excess. Analysis of lysates by LC-MS will help determine the extent to which each
species is formed and modifications to the addition ratio will be made accordingly.
Crotonyl-CoA Carboxylase Reductase: Our backup plan if the PCC method proves
unsuccessful will be to employ a natural enzyme involved in ethylmalonyl-CoA biosynthesis in S.
collinus, CCR. 15,16 This strategy has been used previously in Streptomyces to incorporate a single
ethylmalonate into the backbone of 6-deoxyerythronolide B. 17 By adding the appropriate
precursors to an engineered S. erythraea strain overproducing CCR, they were able to
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demonstrate incorporation of ethylmalonate. A similar strategy will be attempted in our
engineered E. coli system to provide the correct extender units for fluvirucin biosynthesis. As an
interesting side note, the same research team that produced the ethyl analog of 6deoxyerythronolide B observed that the ethylmalonate-specific AT domain would accept
methylmalonate under conditions where ethylmalonyl-CoA was unavailable.17 If the fluvirucin AT
domains exhibit a similar tolerance for methylmalonyl-CoA, the methylated form of the final
product will suffice for all downstream experiments.
With a functional strategy for extender unit construction in place, we will begin assessing
fluvirucin output from our engineered E. coli strain. The N-acetylcysteamine thioester of βalanine (β-Ala-SNAc) will serve as the starter unit for PKS priming. A series of 100 ml cultures of
appropriately engineered BAP1, an E. coli variant with a phosphopantetheinyl transferase
embedded in the genome, will be incubated with β-Ala-SNAc at concentrations ranging from 1
mM to 1 M to determine the optimal conditions for fluvirucin production. Small molecule output
will be assayed using LC-MS following organic extraction of each lysate. Further optimization of
fermentation parameters will be accomplished using additional variables such as culture volume,
incubation temperature, and time. Ultimately, the maximal yield ascertained in these studies will
provide the benchmark for comparison to all mutant forms. Although it is just the beginning of
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our work with this system, successful production of fluvirucin B1 will represent the first
demonstration of heterologous macrolactam generation in E. coli.
We are fully aware that reconstitution of the fluvirucin PKS pathway in E. coli may not be
possible. Although we are thoroughly committed to this host for its genetic simplicity, fast
growth, and the countless tools available for its manipulation, alternate plans are in place if at any
point it becomes clear that our efforts are unproductive. Other bacteria, including S. coelicolor
and S. lividans have also been used to heterologously produce polyketides and may require less
host-engineering than E. coli should this pose a problem. 18 In addition, we will explore the
possibility of a cell-free synthesis of fluvirucin using synthetically-derived starter and extender
units. Although not equivalent to cell-based fluvirucin biosynthesis, this strategy may afford the
desired information regarding the engineering obstacles with little background noise arising from
unrelated cellular metabolites.

5.3.3.2 Mutational Inactivation of Individual Domains for Increased Product Yield

During the biosynthesis of fluvirucin B1, thirteen unique tailoring domains are involved in
β-carbon processing.

In contrast, DEBS relies on only seven of these enzymes for 6-

deoxyerythronolide B production despite harboring an extra module compared to the fluvirucin
PKS. Therefore, if our goal is to manipulate small molecule structure without disrupting native
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protein-protein interactions, mutational inactivation of fluvirucin PKS domains nearly doubles the
product landscape. It has been said that the key to successful combinatorial methods in natural
product biosynthesis lies in the discovery of higher-yielding engineering strategies.19 This section
of our research program will systematically illustrate the benefits of simple mutagenesis to control
polyketide structure (Figure 37). In addition, the relative product yields from each single-point
mutant will begin to uncover when, and to what extent, substrate selectivity plays a role in the

Figure 37. Schematic diagram of our domain deletion-based engineering strategy for
fluvirucin analog production. Active site mutagenesis of KR, DH, and ER domains will result
in site-specific incorporation of ketone, hydroxyl, and olefin functionalities respectively. This
strategy eliminates the need for introduction of heterologous PKS components thus
circumventing the disruption of protein-protein interactions, a major engineering hurdle.
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flow of intermediates along the assembly line. It should be noted that our strategy for mutational
activation is almost exclusively based on work with similar PKS assemblies. However, we are
prepared to take a more exploratory route (i.e. random mutagenesis, alanine scanning, etc.)
should the need arise.
KR domain inactivation: We will initially focus mutagenesis efforts on conserved NADPH
binding residues for inactivation of ketoreductase domains as described in the preliminary studies
section.

Alternatively, most active KR domains harbor a highly conserved catalytic triad,

Ser/Tyr/Lys, which serves to activate the electrophilic carbonyl carbon toward hydride attack. Any
issues encountered with cofactor binding mutants may be resolved by additionally altering these
residues. Disruption of the catalytic triad may also improve kinetics in these modified systems if
KR-recognition of the ACP-bound intermediates slows intermodular transfer. Combinations of
mutations to both the NADPH binding site and catalytic residues will be examined to determine
optimal inactivation parameters.
DH domain inactivation: Although not yet rigorously studied in modular polyketide
synthases, based on work with analogous fatty acid synthases, dehydratase activity likely relies
heavily on a conserved histidine residue acting as a general base on the proton of the β-hydroxyl
group during dehydration. We expect that mutating this residue to any hydrophobic amino acid
such as alanine or leucine will abolish activity.
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ER domain inactivation: Similar to KR domains, enoyl reductases require an NADPH
cofactor for activity. Both single and multiple mutations within this binding site will be examined
to determine the most favorable configuration as above.
Each of the thirteen mutants will be individually assayed using the optimized parameters
for wild-type fluvirucin production elucidated in section 5.3.3.1 (Figure 38). Yields of the
engineered products, relative to the wild-type fluvirucin, will be determined by LC-MS using an
internal standard. Although we do not expect the ionization potentials of these products to be

Figure 38. Structures of the thirteen fluvirucin analogs possible from single domain
inactivations. Each mutation results in site specific modification of macrolactam structure.
Relative yields of these products will provide vital information as to the relative contributions
of the two primary obstacles in polyketide engineering.
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vastly different, standard curves will be prepared for added assurance. Any polyketide products
generated in high enough quantities upon scale-up will be analyzed by 1D and 2D NMR to uncover
any stereochemical trends as they relate to intermodular shuttling of intermediates. We are
aware that, in some cases, the thioesterase domain may not be able to efficiently cyclize the
intended product, resulting in unexpectedly low yields. Every effort will be made to identify and
quantitate hydrolysis products, and plans are in place to utilize alternative thioesterase domains
should the need arise. Our overriding goal is to meet or exceed the highest yields obtained with
the engineered DEBS system (~70% of wild type) for all single mutants of the fluvirucin PKS. 19,20
At these levels, we can confidently state that we have overcome the primary polyketide
engineering hurdles and that realization of functional combinatorial biosynthesis is well within
our grasp.

5.3.4 Engineering FAS-like PKS into Iterative PKS

Similarities between FASs and modular PKS has been studied from the level of the
individual reaction mechanisms to the structures of each catalytic domains and the architectural
organization of the entire enzymatic complexes 21 , 22 , and furthermore, the evolutionary links
between FAS and PKS has been emphasized by comprehensive phylogenetic analyses to show
they may have a common origin.23 Therefore, it is very reasonable to explore the possibility to
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engineer a PKS module into an iterative FAS system, and the successful result could be applied
into metabolic engineering or biofuel production.
In 2012, Khosla and coworkers have “reprogrammed” module 3 of DEBS to catalyze two
successive rounds of chain elongation. 24 However, they could not observe products more than
two iterations, and they hypothesized that the active site of KS3 may not be able to accommodate
substrate longer than triketide. Similarly, Mohanty and colleagues conducted bioinformatic
analyses on 217 pure modular KS domains, 82 pure iterative domains, 19 enediyne, 43 trans-type
and 34 KS domains from hybrid NRPS-PKS clusters, 25 and they have discovered two crucial
positions may govern the chain length in different iterative PKSs. They also combined the
structural information of FAS and PKS to deduce that the size of substrate cavity in KS hold the
key to fully engineer a PKS into a FAS.
We believe that fluvirucin PKS system provides a unique opportunity and potential to be
explored for this purpose. Not only four out of five modules possess the similarity to FAS, but also
they are subdivided into two distinct group which could be useful in terms of bioinformatic
analyses and in vitro experiments.
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5.4 Summary

In this thesis, I seek to examine the relative contributions of the two primary causes of
low yields in polyketide engineering, substrate selectivity and disruption of protein-protein
interactions, issues that have severely limited drug discovery and diversification programs for the
past several decades. In contrast to most traditional PKS systems used for metabolic engineering
efforts, the fluvirucin PKS is composed primarily of fatty acid synthase-like modules which contain
all three β-processing domains (KR, DH, and ER). These enzymes are solely responsible for the
oxidation state of every other carbon on the polyketide chain and, therefore, provide enormous
potential for controlling product variation through genetic engineering. Most importantly,
alterations to polyketide structure can be achieved by simple mutagenesis of key amino acids
which leaves the three-dimensional architecture and all native protein-protein recognition motifs
intact. This is in stark contrast to other, well-studied systems such as DEBS, where obtaining the
desired level of product diversity requires the introduction of heterologous domains and modules
which are not necessarily evolved to communicate with the native components.
Our strategy with the fluvirucin PKS effectively eliminates the disruption of proteinprotein interactions as an engineering hurdle. As a result, we are uniquely positioned to tackle
the second hurdle, substrate selectivity, in isolation.

This challenge requires a thorough

understanding of chain transfer mechanisms between ACP and the downstream KS domain. Using
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the fluorescence assay for KS substrate selectivity and guided by recent structural data, we will
both determine the native substrate tolerance for each fluvirucin KS domain and attempt to alter
or broaden selectivity in those domains exhibiting inherent, thermodynamically-controlled
substrate recognition. By eliminating both of these engineering obstacles, we aspire to obtain
near wild type production levels of fluvirucin B1 analogs. In cases where low yields persist, we
aim to uncover alternative engineering obstacles and ultimately offer a set of universal guidelines
for polyketide structure diversification.
Successful execution of the proposed research program will lead to improved
understanding of chain transfer mechanisms, more clearly-defined approaches for domain
deletion, and the necessary foundation for practical combinatorial biosynthesis. To illustrate the
latter, future efforts will focus on design and implementation of experiments where high-yielding
single KR, DH, and ER mutants are combined to produce usable quantities of novel macrolactams.
Realization of this goal will permit greatly expanded exploration of polyketide functionality and
amass an abundance of diverse macrolide scaffolds for building the next generation of small
molecule therapeutics, and even elucidate the evolution relationship between FASs and PKSs.
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